1
|
Huang J, Zheng H, Zhu X, Zhang K, Ping X. Tenecteplase versus alteplase for the treatment of acute ischemic stroke: a meta-analysis of randomized controlled trials. Ann Med 2024; 56:2320285. [PMID: 38442293 PMCID: PMC10916912 DOI: 10.1080/07853890.2024.2320285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Accepted: 02/13/2024] [Indexed: 03/07/2024] Open
Abstract
OBJECTIVES Tenecteplase, a modified variant of alteplase with greater fibrin specificity and longer plasma half-life, may have better efficacy and safety than alteplase in patients with acute ischemic stroke (AIS). We aimed to compare the benefits and risks of tenecteplase versus alteplase in the treatment of AIS. METHODS Electronic databases were searched up to 10 February 2023 for randomized controlled trials evaluating the effect of tenecteplase versus alteplase in the treatment of AIS. The primary outcome was functional outcome at 90 days, and secondary outcomes including the symptomatic intracranial haemorrhage (SICH), and major neurological improvement. Subgroup analysis was performed based on the different dosage of tenecteplase. RESULTS Ten studies with a total of 5123 patients were analysed in this meta-analysis. Overall, no significant difference between tenecteplase and alteplase was observed for functional outcome at 90 days (excellent: OR 1.08, 95%CI 0.93-1.26, I2 = 26%; good: OR 1.04, 95%CI 0.83-1.30, I2 = 56%; poor: OR 0.95, 95%CI 0.75-1.21, I2 = 31%), SICH (OR 1.12, 95%CI 0.79-1.59, I2 = 0%), and early major neurological improvement (OR 1.26, 95%CI 0.80-1.96, I2 = 65%). The subgroup analysis suggested that the 0.25 mg/kg dose of tenecteplase had potentially greater efficacy and lower symptomatic intracerebral haemorrhage risk compared with 0.25 mg/kg dose tenecteplase. CONCLUSIONS Among AIS patients, there was no significant difference on clinical outcomes between tenecteplase and alteplase. Subgroup analysis demonstrated that 0.25 mg/kg doses of tenecteplase were more beneficial than 0.4 mg/kg doses of tenecteplase. Further studies are required to identify the optimal dosage of tenecteplase.
Collapse
Affiliation(s)
- Jian Huang
- Department of Critical Care Medicine, Hangzhou Ninth People’s Hospital, Hangzhou, China
| | - Hui Zheng
- Department of Emergency Medicine, Hangzhou Ninth People’s Hospital, Hangzhou, China
| | - Xianfeng Zhu
- Department of Critical Care Medicine, Hangzhou Ninth People’s Hospital, Hangzhou, China
| | - Kai Zhang
- Department of Critical Care Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Xiaofeng Ping
- Department of Critical Care Medicine, Hangzhou Ninth People’s Hospital, Hangzhou, China
| |
Collapse
|
2
|
Haj Mohamad Ebrahim Ketabforoush A, Hosseinpour A, Habibi MA, Ariaei A, Farajollahi M, Chegini R, Mirzaasgari Z. Optimizing Acute Ischemic Stroke Outcomes: The Role of Tenecteplase Before Mechanical Thrombectomy. Clin Ther 2024:S0149-2918(24)00223-6. [PMID: 39266330 DOI: 10.1016/j.clinthera.2024.08.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2024] [Revised: 08/09/2024] [Accepted: 08/13/2024] [Indexed: 09/14/2024]
Abstract
PURPOSE Acute ischemic stroke (AIS) is a life-threatening condition demanding prompt reperfusion to salvage brain tissue. Thrombolytic drugs, like tenecteplase (TNK), offer clot dissolution, but time constraints and contraindications limit their use. Mechanical thrombectomy (MT) revolutionized AIS treatment, especially for large vessel occlusions (LVO). Recent evidence suggests that administering TNK before MT improves recanalization and outcomes, challenging the dominance of alteplase. METHODS Relevant articles focusing on TNK before MT were retrieved from PubMed, Scopus, and Web of Science, looking for randomized controlled trials (RCT), clinical trials, and meta-analyses in humans until 2024. FINDINGS TNK, a genetically engineered thrombolytic, exhibits superior fibrin specificity and a longer half-life than alteplase. Clinical trials comparing TNK and alteplase before MT showcase enhanced recanalization, functional outcomes, and safety with TNK. Advanced neuroimaging aids patient selection, though its cost-effectiveness warrants consideration. Dosing studies favor a 0.25 mg/kg dose for efficacy and reduced complications. Clinical guidelines from various associations acknowledge TNK's potential as an alteplase alternative for AIS treatment, particularly for LVOs eligible for thrombectomy. IMPLICATIONS In conclusion, TNK emerges as a promising option for bridging therapy in AIS, displaying efficacy and safety benefits, especially when administered before MT. Its fibrin specificity, longer half-life, and potential for improved outcomes position TNK as a viable alternative to alteplase, potentially transforming the landscape of AIS treatment strategies. While limitations like small sample sizes and variations in protocols exist, future research should focus on large-scale RCT, subgroup analyses, and cost-effectiveness evaluations to further elucidate TNK's role in optimizing AIS management.
Collapse
Affiliation(s)
| | - Ali Hosseinpour
- Department of Neurology, Clinical Research Development Unit (CRDU) of Shahid Rajaei Hospital, Alborz University of Medical Sciences, Karaj, Iran
| | - Mohamad Amin Habibi
- Clinical Research Development Center, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran
| | - Armin Ariaei
- School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | | | - Rojin Chegini
- Metabolic liver disease research center, Isfahan University of medical sciences, Isfahan, Iran
| | - Zahra Mirzaasgari
- Department of Neurology, Firouzgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
3
|
Wiyarta E, Fisher M, Kurniawan M, Hidayat R, Geraldi IP, Khan QA, Widyadharma IPE, Badshah A, Pandian JD. Global Insights on Prehospital Stroke Care: A Comprehensive Review of Challenges and Solutions in Low- and Middle-Income Countries. J Clin Med 2024; 13:4780. [PMID: 39200922 PMCID: PMC11355367 DOI: 10.3390/jcm13164780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2024] [Revised: 08/07/2024] [Accepted: 08/13/2024] [Indexed: 09/02/2024] Open
Abstract
Stroke is a leading cause of disability and mortality worldwide, and it disproportionately affects low- and middle-income countries (LMICs), which account for 88% of stroke fatalities. Prehospital stroke care delays are a crucial obstacle to successful treatment in these settings, especially given the limited therapeutic window for thrombolytic treatments, which may greatly improve recovery chances when initiated early after stroke onset. These delays are caused by a lack of public understanding of stroke symptoms, sociodemographic and cultural variables, and insufficient healthcare infrastructure. This review discusses these issues in detail, emphasizing the disparities in stroke awareness and reaction times between locations and socioeconomic classes. Innovative options for reducing these delays include the deployment of mobile stroke units and community-based educational campaigns. This review also discusses how technology improvements and personalized educational initiatives might improve stroke awareness and response in LMICs. The primary goal is to give a thorough assessment of the challenges and potential remedies that might serve as the foundation for policy reforms and healthcare improvements in LMICs, eventually improving stroke care and lowering disease-related mortality and disability.
Collapse
Affiliation(s)
- Elvan Wiyarta
- Department of Neurology, Faculty of Medicine, Universitas Indonesia-Dr. Cipto Mangunkusumo National Hospital, Central Jakarta, Jakarta 10430, Indonesia; (M.K.); (R.H.)
| | - Marc Fisher
- Beth Israel Deaconess Medical Center, Boston, MA 02215, USA;
| | - Mohammad Kurniawan
- Department of Neurology, Faculty of Medicine, Universitas Indonesia-Dr. Cipto Mangunkusumo National Hospital, Central Jakarta, Jakarta 10430, Indonesia; (M.K.); (R.H.)
| | - Rakhmad Hidayat
- Department of Neurology, Faculty of Medicine, Universitas Indonesia-Dr. Cipto Mangunkusumo National Hospital, Central Jakarta, Jakarta 10430, Indonesia; (M.K.); (R.H.)
| | | | - Qaisar Ali Khan
- Department of Medicine, Khyber Teaching Hospital, Peshawar 25120, Pakistan (A.B.)
| | - I Putu Eka Widyadharma
- Department of Neurology, Faculty of Medicine, Universitas Udayana, Bali 80361, Indonesia
| | - Aliena Badshah
- Department of Medicine, Khyber Teaching Hospital, Peshawar 25120, Pakistan (A.B.)
| | | |
Collapse
|
4
|
Srisurapanont K, Uawithya E, Dhanasomboon P, Pollasen N, Thiankhaw K. Comparative efficacy and safety among different doses of tenecteplase for acute ischemic stroke: A systematic review and network meta-analysis. J Stroke Cerebrovasc Dis 2024; 33:107822. [PMID: 38897370 DOI: 10.1016/j.jstrokecerebrovasdis.2024.107822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2024] [Revised: 05/28/2024] [Accepted: 06/13/2024] [Indexed: 06/21/2024] Open
Abstract
OBJECTIVES Tenecteplase (TNK) is a promising alternative to alteplase (ALT) as the thrombolytic agent for acute ischemic stroke (AIS). However, its clinical outcomes in certain populations remain unclear. This study aimed to compare the efficacy and safety among different doses of TNK in AIS patients. METHODS We searched PubMed, Scopus, Cochrane Central Register of Controlled Trials, and Embase for studies comparing at least one dose of TNK to another dose of TNK or ALT 0.90 mg/kg. We conducted Bayesian network meta-analyses to estimate the relative risks (RRs) and 95% credible intervals (CrIs) for all outcomes using ALT 0.90 mg/kg as the reference. The treatments were ranked according to their surface under the cumulative ranking (SUCRA) values. RESULTS We included 11 trials from 16 publications comprising 5423 participants. There were no significant differences between any doses of TNK and ALT for reperfusion, 3-month modified Rankin Score (mRS) 0-1 (rank 1st: TNK 0.25 mg/kg; SUCRA = 0.68), mRS 0-2 (rank 1st: TNK 0.25 mg/kg; SUCRA = 0.86), mortality (rank 1st: TNK 0.25 mg/kg; SUCRA = 0.82), intracranial hemorrhage (ICH) (rank 1st: TNK 0.25 mg/kg; SUCRA = 0.88), symptomatic ICH (sICH) (rank 1st: TNK 0.10 mg/kg; SUCRA = 0.70), and parenchymal hematoma (rank 1st: TNK 0.10 mg/kg; SUCRA = 0.68). TNK 0.40 mg/kg had a significantly higher sICH rate compared to TNK 0.25 mg/kg (RR = 2.39, 95% CrI = 1.00-7.92). Among elderly patients, TNK 0.25 mg/kg had a significantly lower rate of sICH than ALT 0.9 mg/kg (RR = 3.0 × 10-13, 95% CrI = 3.4 × 10-40-0.07). CONCLUSIONS TNK has efficacy and safety outcomes comparable to those of ALT. TNK 0.25 mg/kg may be the optimal dose of TNK for patients with AIS.
Collapse
Affiliation(s)
| | - Ekdanai Uawithya
- Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | | | | | - Kitti Thiankhaw
- Division of Neurology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, 110, Inthawaroros Road, Sriphum, Chiang Mai, Thailand; The Northern Neuroscience Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
| |
Collapse
|
5
|
Zarzour A, Batot C, Boisseau W, Cho TH, Guillon B, Richard S, Marnat G, Arquizan C, Lapergue B, Weisenburger Lile D. Tenecteplase versus Alteplase before thrombectomy: A comprehensive evaluation of clinical and angiographic impact: Insights from the ETIS registry. J Neuroradiol 2024; 51:101189. [PMID: 38462131 DOI: 10.1016/j.neurad.2024.02.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2024] [Revised: 02/28/2024] [Accepted: 02/29/2024] [Indexed: 03/12/2024]
Abstract
INTRODUCTION Data on prior use of Tenecteplase versus Alteplase in acute stroke management by mechanical thrombectomy are controversial. Our primary objective was to make a comprehensive comparative assessment of clinical and angiographic efficacy and safety outcomes in a large prospective observational study. METHODS We included stroke patients who were eligible for intravenous thrombolysis and endovascular thrombectomy between 2019 and 2021, from an ongoing registry in twenty comprehensive stroke centers in France. We divided patients into two groups based on the thrombolytic agent used (Alteplase vs Tenecteplase). We then compared their treatment times, and their angiographic (TICI scale), clinical (mRS at three months and sICH) and safety outcomes after controlling for potential confounders using propensity score methods. RESULTS We evaluated 1131 patients having undergone thrombectomy for the final analysis, 250 received Tenecteplase and 881 Alteplase. Both groups were of the same median age (75 vs 74 respectively), and had the same baseline NIHSS score (16) and ASPECTS (8). There was no significant difference for First Pass Effect (OR 0.93, 95 % CI 0.76-1.14, p = 0.75), time required for reperfusion (OR 0.03, 95 % CI 0.09-0.16, p = 0.49), or for final reperfusion status. Clinically, functional independence at 90 days was similar in both groups (OR 0.82, 95 % CI 0.61-1.10, p = 0.18) with the same risk of sICH (OR 1.36, 95 % CI 0.77-2.41, p = 0.28). However, Tenecteplase patients had shorter imaging-to-groin puncture times (99 vs 142 min, p < 0.05). CONCLUSIONS Tenecteplase showed no better clinical or angiographic impact on thrombectomy compared to Alteplase. Nevertheless, it appeared associated with a shorter thrombolysis-to-groin puncture time.
Collapse
Affiliation(s)
- Amine Zarzour
- Department of Neurology, Foch Hospital, Versailles Saint-Quentin en Yvelines University, Suresnes, France.
| | - Cedric Batot
- Department of Neurology, Foch Hospital, Versailles Saint-Quentin en Yvelines University, Suresnes, France
| | - William Boisseau
- Stroke Unit Neurology, Hôpital Fondation A. de Rothschild, Université Paris-Cité, Université, Paris-Cité and Université Sorbonne Paris Nord (J.P.D.), INSERM, LVTS, F-75018 Paris, France
| | - Tae-Hee Cho
- From the Department of Stroke Medicine, Université Lyon 1, CREATIS, CNRS UMR 5220-INSERM U1044, INSA-Lyon, Hospices Civils de Lyon, Lyon, France
| | - Benoit Guillon
- Department of Neurology, Stroke Center, University Hospital of Nantes, Nantes, France
| | - Sébastien Richard
- Neurology, Stroke Unit, Université, CIC-P 1433, INSERM U1116, CHRU-Nancy, F-54000 Nancy, France
| | - Gaultier Marnat
- Department of Interventional Neuroradiology, University Hospital of Bordeaux, France
| | - Caroline Arquizan
- Department of Neurology, Stroke center, Hôpital Gui de Chauliac, Montpellier Neuroradiology, France
| | - Bertrand Lapergue
- Department of Neurology, Foch Hospital, Versailles Saint-Quentin en Yvelines University, Suresnes, France
| | | |
Collapse
|
6
|
Dutta A, Gupta S, Chakraborty U, Mondal C, Banerjee S, Das D, Jatua SK, Chakrabarty S, Misra S, Bhattacharya J, Datta SK, Ghosh S, Sanyal D, Sarkar A, Ray BK. Comparative Analysis of Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Multicentric Observational Study from Eastern India. Ann Indian Acad Neurol 2024; 27:269-273. [PMID: 38819417 PMCID: PMC11232826 DOI: 10.4103/aian.aian_59_24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2024] [Revised: 03/31/2024] [Accepted: 04/02/2024] [Indexed: 06/01/2024] Open
Abstract
BACKGROUND Tenecteplase is used as an alternative to alteplase and is considered noninferior for thrombolysis in acute ischemic stroke. OBJECTIVES To compare the effectiveness and adverse effects of tenecteplase and alteplase in the real-world management of acute ischemic stroke. MATERIALS AND METHODS In this retrospective observational study, we collected data from acute ischemic stroke patients admitted in six hospitals in West Bengal, India, and were thrombolysed with tenecteplase or alteplase between July 2021 and June 2022. Demographic data, baseline parameters, hospital course, and 3-month follow-up data were collected. The percentage of patients achieving a score of 0-2 in the modified Ranking scale at 3 months, rate of symptomatic intracranial hemorrhage, and all-cause mortality within 3 months were the main parameters of comparison between the two thrombolytic agents. RESULTS A total of 162 patients were initially included in this study. Eight patients were excluded due to unavailability of follow-up data. Among the remaining patients, 71 patients received tenecteplase and 83 patients received alteplase. There was no statistically significant difference between tenecteplase and alteplase with respect to the percentage of patients achieving functional independence (modified Rankin scale score 0-2) at 3 months (53.5% vs. 60.2%, P = 0.706), rate of symptomatic intracranial hemorrhage (5.6% vs. 10.8%, P = 0.246), and all-cause mortality at 3 months (11.3% vs. 15.7%, P = 0.628). CONCLUSION The effectiveness of tenecteplase is comparable to alteplase in the real-world management of acute ischemic stroke. Symptomatic intracranial hemorrhage and all-cause mortality rates are also similar in real-world practice.
Collapse
Affiliation(s)
- Arpan Dutta
- Department of Neurology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
| | - Subhadeep Gupta
- Department of Neurology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
| | - Uddalak Chakraborty
- Department of Neurology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
| | - Chayan Mondal
- Department of Neurology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
| | - Soumozit Banerjee
- Department of Neurology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
| | - Deep Das
- Department of Neurosciences, Calcutta Medical Research Institute, Kolkata, West Bengal, India
| | - Sanat K. Jatua
- Department of General Medicine, Diamond Harbour Government Medical College and Hospital, Diamond Harbour, West Bengal, India
| | - Susanta Chakrabarty
- Department of General Medicine, Barasat Government Medical College and Hospital, Kolkata, West Bengal, India
| | - Samiran Misra
- Department of General Medicine, Tamralipto Government Medical College and Hospital, Tamluk, West Bengal, India
| | - Jishnu Bhattacharya
- Department of General Medicine, Suri District Hospital, Birbhum, West Bengal, India
| | - Samir K. Datta
- Department of General Medicine, Vidyasagar State General Hospital, Kolkata, West Bengal, India
| | - Somnath Ghosh
- Department of General Medicine, Vidyasagar State General Hospital, Kolkata, West Bengal, India
| | - Debasish Sanyal
- Department of Psychiatry, KPC Medical College and Hospital, Kolkata, West Bengal, India
| | - Arnab Sarkar
- Department of Health and Family Welfare, Public Health Branch, Government of West Bengal, India
| | - Biman K. Ray
- Department of Neurology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
| |
Collapse
|
7
|
Ma Y, Xiang H, Busse JW, Yao M, Guo J, Ge L, Li B, Luo X, Mei F, Liu J, Wang Y, Liu Y, Li W, Zou K, Li L, Sun X. Tenecteplase versus alteplase for acute ischemic stroke: a systematic review and meta-analysis of randomized and non-randomized studies. J Neurol 2024; 271:2309-2323. [PMID: 38436679 DOI: 10.1007/s00415-024-12243-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2024] [Revised: 02/07/2024] [Accepted: 02/07/2024] [Indexed: 03/05/2024]
Abstract
OBJECTIVE Alteplase is the current standard of care for acute ischemic stroke. Tenecteplase is a newer fibrinolytic agent with preferable administration and lower costs; however, its comparative effectiveness to alteplase remains uncertain. We set out to perform a systematic review and meta-analysis to establish the benefits and harms of tenecteplase versus alteplase for acute ischemic stroke. METHODS We searched PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov from inception to April 2023 for randomized and non-randomized studies that compared tenecteplase versus alteplase for acute ischemic stroke. Paired reviewers independently assessed risk of bias and extracted data. We performed both conventional meta-analyses and Bayesian network meta-analyses (NMA) with random-effects models and used the GRADE approach to evaluate the certainty of evidence. Our primary efficacy outcome was excellent functional outcome at 3 months, defined as a score of 0-1 on the modified Rankin Scale. Our primary safety outcomes were symptomatic intracranial hemorrhage and all-cause mortality. RESULTS Thirty-six studies were eligible for review, including 12 randomized (n = 5533) and 24 non-randomized studies (n = 44,956). Moderate certainty evidence showed that there was no difference between tenecteplase and alteplase in increasing the proportion of patients achieving excellent functional outcome at 3 months (odds ratio [OR], 1.10; 95% CI 0.98-1.23; risk difference [RD] 2.4%, 95% CI - 0.5 to 5.2), while moderate certainty evidence from NMA suggested that 0.25 mg/kg tenecteplase significantly improved excellent functional outcome at 3 months (OR, 1.16; 95% credible interval 1.02-1.32). Moderate certainty evidence showed that, compared to alteplase, tenecteplase may make little to no difference in the prevalence of symptomatic intracranial hemorrhage (OR, 1.12; 95% CI 0.79-1.59; RD 0.3%, 95% CI - 0.5 to 1.4), and probably reduces all-cause mortality (adjusted odds ratio [aOR], 0.44; 95% CI 0.30-0.64; RD - 4.6%; 95% CI - 5.8 to - 2.9). CONCLUSIONS Moderate certainty evidence suggested that there was little to no difference between tenecteplase and alteplase in increasing the proportion of patients achieving excellent functional outcome at 3 months and the risk of symptomatic intracranial hemorrhage, while compared to alteplase, tenecteplase probably reduce all-cause mortality. Administration of 0.25 mg/kg tenecteplase after acute ischemic stroke is suggestive of increasing the proportion of patients that achieve excellent functional outcome at 3 months.
Collapse
Affiliation(s)
- Yu Ma
- Department of Neurology and Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China
- NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, 610041, China
- Sichuan Center of Technology Innovation for Real World Data, Chengdu, 610041, China
| | - Hunong Xiang
- Department of Neurology and Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China
- NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, 610041, China
- Sichuan Center of Technology Innovation for Real World Data, Chengdu, 610041, China
| | - Jason W Busse
- Michael G. DeGroote National Pain Centre, McMaster University, Hamilton, ON, L8S 4K1, Canada
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, L8S 4K1, Canada
- Department of Anaesthesia, McMaster University, Hamilton, ON, L8S 4K1, Canada
| | - Minghong Yao
- Department of Neurology and Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China
- NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, 610041, China
- Sichuan Center of Technology Innovation for Real World Data, Chengdu, 610041, China
| | - Jian Guo
- Department of Neurology, West China Hospital, Sichuan University, Chengdu, 610041, China
| | - Long Ge
- Evidence Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, 730000, China
- Department of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou, 730000, China
| | - Bo Li
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300381, China
- National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, 300381, China
| | - Xiaochao Luo
- Department of Neurology and Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China
- NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, 610041, China
- Sichuan Center of Technology Innovation for Real World Data, Chengdu, 610041, China
| | - Fan Mei
- Department of Neurology and Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China
- NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, 610041, China
- Sichuan Center of Technology Innovation for Real World Data, Chengdu, 610041, China
| | - Jiali Liu
- Department of Neurology and Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China
- NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, 610041, China
- Sichuan Center of Technology Innovation for Real World Data, Chengdu, 610041, China
| | - Yuning Wang
- Department of Neurology and Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China
- NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, 610041, China
- Sichuan Center of Technology Innovation for Real World Data, Chengdu, 610041, China
| | - Yanmei Liu
- Department of Neurology and Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China
- NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, 610041, China
- Sichuan Center of Technology Innovation for Real World Data, Chengdu, 610041, China
| | - Wentao Li
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300381, China
- National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, 300381, China
| | - Kang Zou
- Department of Neurology and Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China
- NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, 610041, China
- Sichuan Center of Technology Innovation for Real World Data, Chengdu, 610041, China
| | - Ling Li
- Department of Neurology and Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China.
- NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, 610041, China.
- Sichuan Center of Technology Innovation for Real World Data, Chengdu, 610041, China.
| | - Xin Sun
- Department of Neurology and Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China.
- NMPA Key Laboratory for Real World Data Research and Evaluation in Hainan, Chengdu, 610041, China.
- Sichuan Center of Technology Innovation for Real World Data, Chengdu, 610041, China.
| |
Collapse
|
8
|
Bindal P, Kumar V, Kapil L, Singh C, Singh A. Therapeutic management of ischemic stroke. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 2024; 397:2651-2679. [PMID: 37966570 DOI: 10.1007/s00210-023-02804-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Accepted: 10/19/2023] [Indexed: 11/16/2023]
Abstract
Stroke is the third leading cause of years lost due to disability and the second-largest cause of mortality worldwide. Most occurrences of stroke are brought on by the sudden occlusion of an artery (ischemic stroke), but sometimes they are brought on by bleeding into brain tissue after a blood vessel has ruptured (hemorrhagic stroke). Alteplase is the only therapy the American Food and Drug Administration has approved for ischemic stroke under the thrombolysis category. Current views as well as relevant clinical research on the diagnosis, assessment, and management of stroke are reviewed to suggest appropriate treatment strategies. We searched PubMed and Google Scholar for the available therapeutic regimes in the past, present, and future. With the advent of endovascular therapy in 2015 and intravenous thrombolysis in 1995, the therapeutic options for ischemic stroke have expanded significantly. A novel approach such as vagus nerve stimulation could be life-changing for many stroke patients. Therapeutic hypothermia, the process of cooling the body or brain to preserve organ integrity, is one of the most potent neuroprotectants in both clinical and preclinical contexts. The rapid intervention has been linked to more favorable clinical results. This study focuses on the pathogenesis of stroke, as well as its recent advancements, future prospects, and potential therapeutic targets in stroke therapy.
Collapse
Affiliation(s)
- Priya Bindal
- Department of Pharmacology, ISF College of Pharmacy, Moga 142001, Affiliated to I.K Gujral Punjab Technical University, Jalandhar, Punjab, India
| | - Vishal Kumar
- Department of Pharmacology, ISF College of Pharmacy, Moga 142001, Affiliated to I.K Gujral Punjab Technical University, Jalandhar, Punjab, India
| | - Lakshay Kapil
- Department of Pharmacology, ISF College of Pharmacy, Moga 142001, Affiliated to I.K Gujral Punjab Technical University, Jalandhar, Punjab, India
| | - Charan Singh
- Department of Pharmaceutical Sciences, HNB Garhwal University (A Central University), Chauras Campus, Distt. Tehri Garhwal, Uttarakhand, 246174, India
| | - Arti Singh
- Department of Pharmacology, ISF College of Pharmacy, Moga 142001, Affiliated to I.K Gujral Punjab Technical University, Jalandhar, Punjab, India.
| |
Collapse
|
9
|
Singh A, Singh MP, Gaikwad NR, Kannauje PK. Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Systematic Review and Meta-analysis. Ann Neurosci 2024; 31:132-142. [PMID: 38694719 PMCID: PMC11060130 DOI: 10.1177/09727531231193242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Accepted: 06/14/2023] [Indexed: 05/04/2024] Open
Abstract
Background A number of clinical trials have compared tenecteplase (TNK) and alteplase for the management of acute ischemic stroke (AIS) and the results are inconsistent. Purpose Present systematic review and meta-analysis is undertaken to analyse the efficacy and safety of TNK in AIS compared to alteplase. Summary A thorough literature search was performed through the databases Embase, Cochrane Library, PubMed, and clinicaltrials.gov, for a period from inception to September 2022, with the keywords i.e., "tenecteplase" and "alteplase" and "acute ischemic stroke." Clinical trials published in English that compared the efficacy and safety of TNK to alteplase in AIS were included. The major outcomes of this meta-analysis were proportion of patients free from disability and functional independence at 90 days, early neurological improvement at 24 hours, all-cause mortality at 90 days, patients with intra cranial hemorrhage (ICH), and patients with severe disability at 90 days. A total of nine studies with 3,573 patients were included in the analysis. The proportion of patients with freedom from disability was comparable in both groups (relative risk [RR] = 1.04, 95 per cent CI = 0.92-1.17; p = .53). Similarly, proportion of patients with functional independence was comparable (RR = 1.12, 95 per cent CI = 0.96-1.31; p = .14). TNK group had a higher rate of early neurological recovery (RR = 1.56, 95 per cent CI = 0.96-2.54; p = .07). All-cause mortality at 90 days was comparable in both groups (RR = 0.97; 95 per cent CI = 0.72-1.29; p = .82). The proportion of patients with ICH was higher in TNK group (RR = 1.14, 95 per cent CI = 0.77-1.68; p = .52). The proportion of patients with severe disability was less in TNK group (RR =0.84, 95 per cent CI = 0.53-1.32; p = .44). Key Message TNK was similar to alteplase in terms of efficacy and safety. The patients in TNK group showed early neurological improvement but were simultaneously at higher risk of ICH. The TNK can be an alternative to alteplase if the benefits outweigh the risks.
Collapse
Affiliation(s)
- Alok Singh
- Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India
| | - Madhusudan Prasad Singh
- Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India
| | - Nitin R. Gaikwad
- Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India
| | - Pankaj Kumar Kannauje
- Department of General Medicine, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India
| |
Collapse
|
10
|
Prasad S, Jones EM, Gebreyohanns M, Kwon Y, Olson DM, Anderson JA, Savitz SI, Cruz-Flores S, Warach SJ, Rhodes CE, Goldberg MP, Ifejika NL. Multicenter exploration of tenecteplase transition factors: A quantitative analysis. J Stroke Cerebrovasc Dis 2024; 33:107592. [PMID: 38266690 DOI: 10.1016/j.jstrokecerebrovasdis.2024.107592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Revised: 01/02/2024] [Accepted: 01/20/2024] [Indexed: 01/26/2024] Open
Abstract
BACKGROUND Tenecteplase (TNK) is gaining recognition as a novel therapy for acute ischemic stroke (AIS). Despite TNK offering a longer half-life, time and cost saving benefits and comparable treatment and safety profiles to Alteplase (ALT), the adoption of TNK as a treatment for AIS presents challenges for hospital systems. OBJECTIVE Identify barriers and facilitators of TNK implementation at acute care hospitals in Texas. METHODS This prospective survey used open-ended questions and Likert statements generated from content experts and informed by qualitative research. Stroke clinicians and nurses working at 40 different hospitals in Texas were surveyed using a virtual platform. RESULTS The 40 hospitals had a median of 34 (IQR 24.5-49) emergency department beds and 42.5 (IQR 23.5-64.5) inpatient stroke beds with 506.5 (IQR 350-797.5) annual stroke admissions. Fifty percent of the hospitals were Comprehensive Stroke Centers, and 18 (45 %) were solely using ALT for treatment of eligible AIS patients. Primary facilitators to TNK transition were team buy-in and a willingness of stroke physicians, nurses, and pharmacists to adopt TNK. Leading barriers were lack of clinical evidence supporting TNK safety profile inadequate evidence supporting TNK use and a lack of American Heart Association guidelines support for TNK administration in all AIS cases. CONCLUSION Understanding common barriers and facilitators to TNK adoption can assist acute care hospitals deciding to implement TNK as a treatment for AIS. These findings will be used to design a TNK adoption Toolkit, utilizing implementation science techniques, to address identified obstacles and to leverage facilitators.
Collapse
Affiliation(s)
- Sidarrth Prasad
- University of Texas Southwestern Medical Center, United States
| | - Erica M Jones
- University of Texas Southwestern Medical Center, United States
| | | | - Yoon Kwon
- University of Texas Southwestern Medical Center, United States
| | - DaiWai M Olson
- University of Texas Southwestern Medical Center, United States
| | | | - Sean I Savitz
- University of Texas Health Science Center at Houston, United States
| | | | - Steven J Warach
- Dell Medical School, The University of Texas at Austin, United States
| | - Charlotte E Rhodes
- The University of Texas Health Science Center at San Antonio, United States
| | - Mark P Goldberg
- The University of Texas Health Science Center at San Antonio, United States
| | - Nneka L Ifejika
- University of Texas Southwestern Medical Center, United States.
| |
Collapse
|
11
|
Bhatia R, Srivastava MVP, Fatima S, Sarkar R, Longkumer I, Gaikwad S, Devaranjan LSJ, Garg A, Durai Pandian J, Khurana D, Sylaja PN, Jain S, Arora D, Dhasan A, Aaron S, Miraclin AT, Vijaya P, Rajendran SP, Roy J, Ray BK, Nambiar V, Alapatt PJ, Sharma M. RE-OPEN: Randomised trial of biosimilar TNK versus TPA during endovascular therapy for acute ischaemic stroke due to large vessel occlusions. BMJ Neurol Open 2024; 6:e000531. [PMID: 38501129 PMCID: PMC10946358 DOI: 10.1136/bmjno-2023-000531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2023] [Accepted: 10/08/2023] [Indexed: 03/20/2024] Open
Abstract
Rationale Rapid and timely treatment with intravenous thrombolysis and endovascular treatment (EVT) in patients with acute ischaemic stroke (AIS) and large vessel occlusion (LVO) significantly improves patient outcomes. Bridging therapy is the current standard of care in these patients. However, an incompletely answered question is whether one thrombolytic agent is better than another during bridging therapy. Aim The current study aims to understand if one thrombolytic agent is superior to the other during bridging therapy in the treatment of AIS and LVO. Sample size estimates Using 80% power and an alpha error of 5 %, presuming a 10% drop out rate, a total of 372 patients will be recruited for the study. Methods and design This study is a prospective, randomised, multicentre, open-label trial with blinded outcome analysis design. Study outcomes The primary outcomes include proportion of patients who will be independent at 3 months (modified Rankin score (mRS) ≤2 as good outcome) and proportion of patients who achieve recanalisation modified thrombolysis in cerebral infarction grade 2b/3 at first angiography run at the end of EVT. Secondary outcomes include proportion of patients with early neurological improvement, rate of symptomatic intracerebral haemorrhage (ICH), rate of any ICH, rate of any systemic major or minor bleeding and duration of hospital stay. Safety outcomes include any intracranial bleeding or symptomatic ICH. Discussion This trial is envisioned to confirm the theoretical advantages and increase the strength and quality of evidence for use of tenecteplase (TNK) in practice. Also, it will help to generate data on the efficacy and safety of biosimilar TNK. Trial registration number CTRI/2022/01/039473.
Collapse
Affiliation(s)
- Rohit Bhatia
- Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
| | - MV Padma Srivastava
- Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
| | - Saman Fatima
- Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
| | - Risha Sarkar
- Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
| | - Imnameren Longkumer
- Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
| | - Shailesh Gaikwad
- Department of Neuroimaging and Interventional Neuroradiology, All India Institute of Medical Sciences, New Delhi, India
| | - Leve S Joseph Devaranjan
- Department of Neuroimaging and Interventional Neuroradiology, All India Institute of Medical Sciences, New Delhi, India
| | - Ajay Garg
- Department of Neuroimaging and Interventional Neuroradiology, All India Institute of Medical Sciences, New Delhi, India
| | | | - Dheeraj Khurana
- Department of Neurology, Post Graduate Institute of Medical Education & Research, Chandigarh, India
| | - PN Sylaja
- Department of Neurology, Sree Chitra Tirunal Institute of Medical Sciences & Technology, Thiruvananthapuram, India
| | - Shweta Jain
- Department of Neurology, Christian Medical College, Ludhiana, India
| | - Deepti Arora
- Department of Neurology, Christian Medical College, Ludhiana, India
| | - Aneesh Dhasan
- Department of Neurology, Sree Chitra Tirunal Institute of Medical Sciences & Technology, Thiruvananthapuram, India
| | - Sanjith Aaron
- Department of Neurology, Christian Medical College, Vellore, India
| | - Angel T Miraclin
- Department of Neurology, Christian Medical College, Vellore, India
| | | | - Srijithesh P Rajendran
- Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, India
| | - Jayanta Roy
- Department of Neurology, Institute of Neurosciences, Kolkata, India
| | - Biman Kanti Ray
- Department of Neurology, Bangur Institute of Neurosciences and IPGMER, Kolkata, India
| | - Vivek Nambiar
- Department of Neurology, Amrita Institute of Medical Sciences, Kochi, India
| | | | | |
Collapse
|
12
|
Brown CS, Manuel FC, Mattson AE, Schmitt CJ, Hellickson JD, Clark SL, Wieruszewski ED. Implementation of Tenecteplase for Acute Ischemic Stroke Treatment. J Emerg Nurs 2024; 50:171-177. [PMID: 38069957 DOI: 10.1016/j.jen.2023.11.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 10/04/2023] [Accepted: 11/08/2023] [Indexed: 03/09/2024]
Abstract
INTRODUCTION Acute ischemic stroke is a neurologic emergency, requiring rapid recognition and treatment with intravenous thrombolysis. Since the publication of the 2019 American Heart Association/American Stroke Association Guidelines that recommend tenecteplase as an alternative agent, several centers across the United States are transitioning from alteplase to tenecteplase as the agent of choice for thrombolysis in acute ischemic stroke. METHODS Our health system transitioned to tenecteplase for the treatment of acute ischemic stroke in 2021 due to increasing evidence for efficacy and potential for improved door-to-needle time. Herein we describe our experience and provide guidance for other institutions to implement this change. CONCLUSION Emergency nurses are vital to the care of acute ischemic stroke patients. There are several pharmacologic and logistical differences between alteplase and tenecteplase for this indication. This paper outlines these key differences.
Collapse
|
13
|
Miao ZW, Wang Z, Zheng SL, Wang SN, Miao CY. Anti-stroke biologics: from recombinant proteins to stem cells and organoids. Stroke Vasc Neurol 2024:svn-2023-002883. [PMID: 38286483 DOI: 10.1136/svn-2023-002883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2023] [Accepted: 12/26/2023] [Indexed: 01/31/2024] Open
Abstract
The use of biologics in various diseases has dramatically increased in recent years. Stroke, a cerebrovascular disease, is the second most common cause of death, and the leading cause of disability with high morbidity worldwide. For biologics applied in the treatment of acute ischaemic stroke, alteplase is the only thrombolytic agent. Meanwhile, current clinical trials show that two recombinant proteins, tenecteplase and non-immunogenic staphylokinase, are most promising as new thrombolytic agents for acute ischaemic stroke therapy. In addition, stem cell-based therapy, which uses stem cells or organoids for stroke treatment, has shown promising results in preclinical and early clinical studies. These strategies for acute ischaemic stroke mainly rely on the unique properties of undifferentiated cells to facilitate tissue repair and regeneration. However, there is a still considerable journey ahead before these approaches become routine clinical use. This includes optimising cell delivery methods, determining the ideal cell type and dosage, and addressing long-term safety concerns. This review introduces the current or promising recombinant proteins for thrombolysis therapy in ischaemic stroke and highlights the promise and challenges of stem cells and cerebral organoids in stroke therapy.
Collapse
Affiliation(s)
- Zhu-Wei Miao
- Department of Pharmacology, Second Military Medical University/ Naval Medical University, Shanghai, China
| | - Zhi Wang
- Department of Pharmacology, Second Military Medical University/ Naval Medical University, Shanghai, China
| | - Si-Li Zheng
- Department of Pharmacology, Second Military Medical University/ Naval Medical University, Shanghai, China
| | - Shu-Na Wang
- Department of Pharmacology, Second Military Medical University/ Naval Medical University, Shanghai, China
| | - Chao-Yu Miao
- Department of Pharmacology, Second Military Medical University/ Naval Medical University, Shanghai, China
| |
Collapse
|
14
|
Baena-Caldas GP, Li J, Pedraza L, Ghosh S, Kalmes A, Barone FC, Moreno H, Hernández AI. Neuroprotective effect of the RNS60 in a mouse model of transient focal cerebral ischemia. PLoS One 2024; 19:e0295504. [PMID: 38166102 PMCID: PMC10760892 DOI: 10.1371/journal.pone.0295504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2022] [Accepted: 11/22/2023] [Indexed: 01/04/2024] Open
Abstract
BACKGROUND Stroke is a major cause of death, disability, and public health problems. Its intervention is limited to early treatment with thrombolytics and/or endovascular clot removal with mechanical thrombectomy without any available subacute or chronic neuroprotective treatments. RNS60 has reduced neuroinflammation and increased neuronal survival in several animal models of neurodegeneration and trauma. The aim here was to evaluate whether RNS60 protects the brain and cognitive function in a mouse stroke model. METHODS Male C57BL/6J mice were subjected to sham or ischemic stroke surgery using 60-minute transient middle cerebral artery occlusion (tMCAo). In each group, mice received blinded daily administrations of RNS60 or control fluids (PNS60 or normal saline [NS]), beginning 2 hours after surgery over 13 days. Multiple neurobehavioral tests were conducted (Neurological Severity Score [mNSS], Novel Object Recognition [NOR], Active Place Avoidance [APA], and the Conflict Variant of APA [APAc]). On day 14, cortical microvascular perfusion (MVP) was measured, then brains were removed and infarct volume, immunofluorescence of amyloid beta (Aβ), neuronal density, microglial activation, and white matter damage/myelination were measured. SPSS was used for analysis (e.g., ANOVA for parametric data; Kruskal Wallis for non-parametric data; with post-hoc analysis). RESULTS Thirteen days of treatment with RNS60 reduced brain infarction, amyloid pathology, neuronal death, microglial activation, white matter damage, and increased MVP. RNS60 reduced brain pathology and resulted in behavioral improvements in stroke compared to sham surgery mice (increased memory-learning in NOR and APA, improved cognitive flexibility in APAc). CONCLUSION RNS60-treated mice exhibit significant protection of brain tissue and improved neurobehavioral functioning after tMCAo-stroke. Additional work is required to determine mechanisms, time-window of dosing, and multiple dosing volumes durations to support clinical stroke research.
Collapse
Affiliation(s)
- Gloria Patricia Baena-Caldas
- Departments of Neurology and Physiology & Pharmacology, SUNY Downstate Health Sciences University, Brooklyn, NY, United States of America
- Department of Pathology, SUNY Downstate Health Sciences University, Brooklyn, NY, United States of America
- Health Sciences Division, Department of Morphology, School of Biomedical Sciences, Universidad del Valle, Cali, Colombia
| | - Jie Li
- Departments of Neurology and Physiology & Pharmacology, SUNY Downstate Health Sciences University, Brooklyn, NY, United States of America
| | - Lina Pedraza
- Departments of Neurology and Physiology & Pharmacology, SUNY Downstate Health Sciences University, Brooklyn, NY, United States of America
| | - Supurna Ghosh
- Revalesio Corporation, Tacoma, WA, United States of America
| | - Andreas Kalmes
- Revalesio Corporation, Tacoma, WA, United States of America
| | - Frank C. Barone
- Departments of Neurology and Physiology & Pharmacology, SUNY Downstate Health Sciences University, Brooklyn, NY, United States of America
- The Robert F. Furchgott Center for Neural and Behavioral Science, Downstate Medical Center, State University of New York, Brooklyn, NY, United States of America
| | - Herman Moreno
- Departments of Neurology and Physiology & Pharmacology, SUNY Downstate Health Sciences University, Brooklyn, NY, United States of America
- The Robert F. Furchgott Center for Neural and Behavioral Science, Downstate Medical Center, State University of New York, Brooklyn, NY, United States of America
| | - A. Iván Hernández
- Department of Pathology, SUNY Downstate Health Sciences University, Brooklyn, NY, United States of America
- The Robert F. Furchgott Center for Neural and Behavioral Science, Downstate Medical Center, State University of New York, Brooklyn, NY, United States of America
| |
Collapse
|
15
|
Zhang X, Wan TF, Chen J, Liu L. Tenecteplase versus alteplase for patients with acute ischemic stroke: a meta-analysis of randomized controlled trials. Aging (Albany NY) 2023; 15:14889-14899. [PMID: 38149983 PMCID: PMC10781500 DOI: 10.18632/aging.205315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Accepted: 11/06/2023] [Indexed: 12/28/2023]
Abstract
Tenecteplase (TNK), a newer fibrinolytic agent with greater fibrin specificity and longer half-life than alteplase, may has practical advantages over alteplase in acute ischemic stroke (AIS) thrombolysis. We aimed to perform a systematic review and meta-analysis of randomized controlled trials (RCTs) to compare different doses of TNK (0.1, 0.25, 0.4 mg/kg) and alteplase in acute ischemic stroke patients. We systematically searched PubMed, Embase and https://clinicaltrials.gov/ for RCTs comparing TNK with alteplase in this population eligible for thrombolysis. The Cochrane Risk of Bias Tool was used to assess study quality. Random-effects or fixed-effects meta-analysis models were used for evaluating all outcomes. Total 10 RCTs with 5097 patients were included. Compared with alteplase, TNK at doses of 0.25 mg/kg may associated with the greatest odds to achieve 90-day excellent independence (mRS score ≤1), but there were no significant differences between other doses of TNK (0.1 mg/kg and 0.4 mg/kg) and alteplase. Among secondary outcomes, no significant differences were found in functional outcome (mRS score ≤2) and mortality at 90 days between any dose of TNK and alteplase. Compared with alteplase, TNK was effective at doses of 0.1 mg/kg and 0.25 mg/kg without increased risk of symptomatic intracerebral hemorrhage (sICH), but patients treated with TNK 0.4 mg/kg showed increased odds of sICH. In conclusion, compared with alteplase, intravenous thrombolysis with TNK at dose of 0.25 mg/kg has a better efficacy and similar safety profile and is a reasonable option for patients with AIS.
Collapse
Affiliation(s)
- Xu Zhang
- Department of Cardiac Surgery, The General Hospital of Northern Theater Command, Shenyang, Liaoning 110000, China
| | - Teng-Fei Wan
- Department of Nursing, Xinqiao Hospital, Chongqing 400037, China
- Department of Critical Care Medicine, The General Hospital of Northern Theater Command, Shenyang, Liaoning 110000, China
| | - Jing Chen
- Department of Neurology, Central Hospital of Baoji, Baoji, Shaanxi 721000, China
| | - Liang Liu
- Department of Neurology, The General Hospital of Northern Theater Command, Shenyang, Liaoning 110016, China
| |
Collapse
|
16
|
Jacobsen E, Logallo N, Kvistad CE, Thomassen L, Idicula T. Characteristics and predictors of stroke mimics in young patients in the norwegian tenecteplase stroke trial (NOR-TEST). BMC Neurol 2023; 23:406. [PMID: 37968581 PMCID: PMC10647039 DOI: 10.1186/s12883-023-03425-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Accepted: 10/05/2023] [Indexed: 11/17/2023] Open
Abstract
BACKGROUND Several studies have shown that stroke mimics occur more often among young patients. Our aims were to identify the common mimics in young patients under the age of 60 years who received thrombolysis, to analyze the risk of hemorrhage after treatment with thrombolysis, and to identify risk factors and clinical parameters that might identify mimics in this group. METHODS Norwegian Tenecteplase Stroke Trial was a phase-3 trial investigating safety and efficacy of tenecteplase vs. alteplase in patients with acute ischemic stroke. Patients diagnosed with either acute cerebral ischemia or transient ischemic attack were categorized as stroke group, and patients with any diagnosis other than ischemic stroke or transient ischemic attack as mimics group. Patients were grouped post-hoc into young (< 60 years) and old (≥ 60 years). Logistic regression analyses were performed with mimics vs. stroke as dependent variable to identify predictors of mimics. RESULTS Of the 1091 patients included in the trial, 211 patients (19.3%) were under the age of 60 years. Out of the 1091 patients, 434 (39.8%) were female, median age 77 years (18-99 years), and median NIHSS was 4. Sixty-nine patients (32.7%) out of the 211 patients under the age of 60 were diagnosed as mimic. Mimics were significantly more frequent among the young (OR = 3.3, 32.7% vs. 12.8%, p = < 0.001). The most frequent mimics diagnoses among patients under 60 years of age were migraine (11.8%), no definite diagnosis (11.4%) and peripheral vertigo (3.3%). Mimics were independently associated with age < 50 years (OR = 4.97, p = < 0.001), not currently working/studying (OR = 3.38, p = 0.002) and not having aphasia on admission (OR = 2.95, p = 0.025). None of the mimics under the age of 60 years had symptomatic or asymptomatic intracerebral hemorrhage as a complication to thrombolysis. CONCLUSION We found significantly more mimics in the young, of which migraine was the most predominant diagnosis. Thrombolysis with alteplase or tenecteplase did not cause ICH in any mimics under 60 years.
Collapse
Affiliation(s)
- Eskil Jacobsen
- Norwegian University of Science and Technology, Trondheim (NTNU), Trondheim, 7034, Norway.
| | - Nicola Logallo
- Department of Neurology, Centre for Neurovascular Diseases, Haukeland University Hospital, Bergen, 5021, Norway
| | - Christopher Elnan Kvistad
- Department of Neurology, Centre for Neurovascular Diseases, Haukeland University Hospital, Bergen, 5021, Norway
- Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Lars Thomassen
- Department of Neurology, Centre for Neurovascular Diseases, Haukeland University Hospital, Bergen, 5021, Norway
- Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Titto Idicula
- Norwegian University of Science and Technology (NTNU), Trondheim, 7034, Norway
- Department of Neurology, St Olav University Hospital, Trondheim, Norway
| |
Collapse
|
17
|
Shen Z, Bao N, Tang M, Yang Y, Li J, Liu W, Jiang G. Tenecteplase vs. Alteplase for Intravenous Thrombolytic Therapy of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Neurol Ther 2023; 12:1553-1572. [PMID: 37552459 PMCID: PMC10444744 DOI: 10.1007/s40120-023-00530-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/11/2023] [Accepted: 07/25/2023] [Indexed: 08/09/2023] Open
Abstract
INTRODUCTION In recent years, as one of the drugs for the treatment of acute ischemic stroke (AIS), the clinical application of tenecteplase is still controversial. Therefore, we aimed to evaluate the safety and efficacy of tenecteplase versus alteplase to guide clinical practice. METHODS A search of PubMed, MEDLINE, EMBASE, Cochrane Library, and Web of Science databases until February 15, 2023 was conducted to identify eligible articles. The quality of the included studies was assessed using the Cochrane Risk of Bias tool. RevMan 5.3 and Stata 17 were used to perform the meta-analysis and detect publication bias, and risk ratios (RRs) with 95% confidence intervals (95% CIs) were reported for each outcome measure. RESULTS A total of 1326 records were retrieved in this meta-analysis. As a result of the limited reports on tenecteplase in patients with AIS and the lack of high-quality randomized controlled trials (RCTs), and considering the impact of publication bias, we did not include any of these studies published before 2015. Ultimately we included 16 RCTs with a total of 7508 patients, including 3940 patients treated with alteplase and 3568 patients treated with tenecteplase. Tenecteplase was associated with better early neurological improvement (RR 0.10; 95% CI 0.00-0.19; P = 0.04), recanalization of blood vessels (RR 0.24; 95% CI 0.07-0.40; P = 0.01), and 90-day excellent neurological recovery (RR 0.12; 95% CI 0.01-0.24; P = 0.04). In addition, there were no significant differences in other efficacy and safety outcomes between the two groups. The funnel plot and Begg's as well as Egger's tests showed no significant publication bias. CONCLUSIONS This meta-analysis showed that tenecteplase was not inferior to alteplase in early thrombolytic therapy in patients with AIS, and was even better than alteplase on some efficacy outcomes with no significant differences in safety. However, as a result of some inherent limitations of this study, more high-quality prospective clinical studies are needed to confirm these results.
Collapse
Affiliation(s)
- Ziyi Shen
- Department of Neurology, Affiliated Hospital of North Sichuan Medical College, 1 South Maoyuan Road, Nanchong, Sichuan, 637000, China
- Institute of Neurological Diseases, North Sichuan Medical College, Nanchong, Sichuan, China
| | - Nana Bao
- Department of Neurology, Affiliated Hospital of North Sichuan Medical College, 1 South Maoyuan Road, Nanchong, Sichuan, 637000, China
- Institute of Neurological Diseases, North Sichuan Medical College, Nanchong, Sichuan, China
| | - Ming Tang
- Department of Neurology, Affiliated Hospital of North Sichuan Medical College, 1 South Maoyuan Road, Nanchong, Sichuan, 637000, China
- Institute of Neurological Diseases, North Sichuan Medical College, Nanchong, Sichuan, China
| | - Yang Yang
- Department of Neurology, Affiliated Hospital of North Sichuan Medical College, 1 South Maoyuan Road, Nanchong, Sichuan, 637000, China
- Institute of Neurological Diseases, North Sichuan Medical College, Nanchong, Sichuan, China
| | - Jia Li
- Department of Neurology, Affiliated Hospital of North Sichuan Medical College, 1 South Maoyuan Road, Nanchong, Sichuan, 637000, China
- Institute of Neurological Diseases, North Sichuan Medical College, Nanchong, Sichuan, China
| | - Wei Liu
- Department of Neurology, Nanbu County Hospital Affiliated to North Sichuan Medical College, Nanchong, Sichuan, China.
| | - Guohui Jiang
- Department of Neurology, Affiliated Hospital of North Sichuan Medical College, 1 South Maoyuan Road, Nanchong, Sichuan, 637000, China.
- Institute of Neurological Diseases, North Sichuan Medical College, Nanchong, Sichuan, China.
| |
Collapse
|
18
|
Nguyen CP, Lahr MMH, van der Zee DJ, van Voorst H, Roos YBWEM, Uyttenboogaart M, Buskens E. Cost-effectiveness of tenecteplase versus alteplase for acute ischemic stroke. Eur Stroke J 2023; 8:638-646. [PMID: 37641549 PMCID: PMC10472948 DOI: 10.1177/23969873231174943] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Accepted: 04/24/2023] [Indexed: 08/31/2023] Open
Abstract
INTRODUCTION Alteplase is widely used as an intravenous thrombolytic drug in acute ischemic stroke (AIS). Recently however, tenecteplase, a modified form of tissue plasminogen activator, has been shown to increase early recanalization rate and has proven to be non-inferior with a similar safety profile compared to alteplase. This study aims to evaluate the cost-effectiveness of 0.25 mg/kg tenecteplase versus 0.9 mg/kg alteplase for intravenous thrombolysis in AIS patients from the Dutch healthcare payer perspective. METHODS A Markov decision-analytic model was constructed to assess total costs, total quality-adjusted life year (QALY), an incremental cost-effectiveness ratio, and incremental net monetary benefit (INMB) of two treatments at willingness-to-pay (WTP) thresholds of €50,000/QALY and €80,000/QALY over a 10-year time horizon. One-way sensitivity analysis, probabilistic sensitivity analysis, and scenario analysis were conducted to test the robustness of results. Clinical data were obtained from large randomized controlled trials and real-world data. RESULTS Treatment with tenecteplase saved €21 per patient while gaining 0.05 QALYs, resulting in INMB of €2381, clearly rendering tenecteplase cost-effective compared to alteplase. Importantly, tenecteplase remained the cost-effective alternative in all scenarios, including AIS patients due to large vessel occlusion (LVO). Probabilistic sensitivity analysis proved tenecteplase to be cost-effective with a 71.0% probability at a WTP threshold of €50,000/QALY. CONCLUSIONS Tenecteplase treatment was cost-effective for all AIS patients (including AIS patients with LVO) compared to alteplase. The finding supports the broader use of tenecteplase in acute stroke care, as health outcomes improve at acceptable costs while having practical advantages, and a similar safety profile.
Collapse
Affiliation(s)
- Chi Phuong Nguyen
- Department of Operations, Faculty of Economics and Business, University of Groningen, Groningen, The Netherlands
- Health Technology Assessment, Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
- Department of Pharmaceutical Management and Economic, Hanoi University of Pharmacy, Vietnam
| | - Maarten MH Lahr
- Health Technology Assessment, Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - Durk-Jouke van der Zee
- Department of Operations, Faculty of Economics and Business, University of Groningen, Groningen, The Netherlands
- Health Technology Assessment, Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - Henk van Voorst
- Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Location University of Amsterdam, Amsterdam, The Netherlands
- Department of Biomedical Engineering and Physics, Amsterdam University Medical Center, Location University of Amsterdam, Amsterdam, The Netherlands
| | - Yvo BWEM Roos
- Department of Neurology, Amsterdam University Medical Center, Location University of Amsterdam, Amsterdam, The Netherlands
| | - Maarten Uyttenboogaart
- Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
- Department of Radiology, Medical Imaging Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - Erik Buskens
- Department of Operations, Faculty of Economics and Business, University of Groningen, Groningen, The Netherlands
- Health Technology Assessment, Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| |
Collapse
|
19
|
Wei H, Fu B, Yang C, Huang M. The efficacy and safety of intravenous thrombolysis with tenecteplase versus alteplase for acute ischemic stroke: a systematic review and meta-analysis. Neurol Sci 2023; 44:3005-3015. [PMID: 37061572 DOI: 10.1007/s10072-023-06801-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Accepted: 04/03/2023] [Indexed: 04/17/2023]
Abstract
OBJECTIVES We aimed to evaluate the available evidence on the efficacy and safety outcomes of intravenous tenecteplase (TNK) compared with intravenous alteplase(ALT) for patients with acute ischemic stroke (AIS) in randomized controlled trials (RCTs). METHODS The MEDLINE/PubMed, Embase, Springer, Web of Science, Cochrane Collaboration database, China National Knowledge Infrastructure (CNKI) database, and Wanfang database were comprehensively searched for RCTs regarding the effects of TNK versus ALT among AIS patients in these English and Chinese electronic databases from inception dates to August 1, 2022. This meta-analysis followed PRISMA guidelines. Two reviewers independently retrieved RCTs and extracted relevant information. The methodological quality of the included trials was estimated using the Cochrane risk of bias tool. The pooled analyses were performed using RevMan 5.3 software. The primary outcome was functional outcome on the modified Rankin Scale (mRS) (range 0 to 5) and mortality at 90 days. The secondary outcomes included successful recanalization, early neurologic improvement < 48 h, any intracranial hemorrhage (ICH), and symptomatic ICH. The follow-up time of all studies was at least 3 months. RESULTS A total of nine RCTs involving 1958 patients in TNK group and 1731 patients in ALT group were finally included. For the efficacy outcomes, there were no significant differences between the two groups in terms of mRS score 0 ~ 2 (RR 1.00; 95% CI 0.88-1.13; P = 0.96), mRS score 0 ~ 1 (RR 1.03; 95% CI 0.96-1.10; P = 0.36), successful recanalization (RR 1.25; 95% CI 0.88-1.76; P = 0.21), and early neurologic improvement < 48 h (RR 1.08; 95% CI 0.92-1.26; P = 0.37). Similar results were seen for the safety outcomes, which have no statistical differences in terms of any ICH (RR 1.01; 95% CI 0.72-1.41; P = 0.96), symptomatic ICH (RR 1.19; 95% CI 0.81-1.76; P = 0.37), and mortality at 90 days (RR 0.99; 95% CI 0.83-1.19; P = 0.94). CONCLUSION Overall, the efficacy and safety outcomes of intravenous thrombolysis with TNK versus ALT for AIS were not statistically different. However, TNK at a dose of 0.25 mg/kg may be a reasonable alternative to ALT for thrombolysis.
Collapse
Affiliation(s)
- Heng Wei
- Department of Neurology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Hubei University of Chinese Medicine, Wuhan, 430000, China.
| | - Bin Fu
- Department of Neurology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Hubei University of Chinese Medicine, Wuhan, 430000, China
| | - Chao Yang
- Department of Neurology, People's Hospital of Dongxihu District of Wuhan Union Hospital, Wuhan, 430040, China
| | - Ming Huang
- Department of Neurology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Hubei University of Chinese Medicine, Wuhan, 430000, China.
| |
Collapse
|
20
|
Lo BM, Carpenter CR, Ducey S, Gottlieb M, Kaji A, Diercks DB, Diercks DB, Wolf SJ, Anderson JD, Byyny R, Carpenter CR, Friedman B, Gemme SR, Gerardo CJ, Godwin SA, Hahn SA, Hatten BW, Haukoos JS, Kaji A, Kwok H, Lo BM, Mace SE, Moran M, Promes SB, Shah KH, Shih RD, Silvers SM, Slivinski A, Smith MD, Thiessen MEW, Tomaszewski CA, Trent S, Valente JH, Wall SP, Westafer LM, Yu Y, Cantrill SV, Finnell JT, Schulz T, Vandertulip K. Clinical Policy: Critical Issues in the Management of Adult Patients Presenting to the Emergency Department With Acute Ischemic Stroke. Ann Emerg Med 2023; 82:e17-e64. [PMID: 37479410 DOI: 10.1016/j.annemergmed.2023.03.007] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/23/2023]
|
21
|
Warach SJ, Ranta A, Kim J, Song SS, Wallace A, Beharry J, Gibson D, Cadilhac DA, Bladin CF, Kleinig TJ, Harvey J, Palanikumar L, Doss VT, Marescalco R, Fink JN, Tyson A, Schlick KH, Noh L, Wilson D, Figueroa S, Pech MA, Paletz LB, Lewis MK, Castro M, Sahlein DH, Lafranchise EF, Sandall J, Asif KS, Geraghty SR, Cullis PA, Malisch T, Neill TA, LaMonte MP, Campbell BCV, Wu TY. Symptomatic Intracranial Hemorrhage With Tenecteplase vs Alteplase in Patients With Acute Ischemic Stroke: The Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) Collaboration. JAMA Neurol 2023; 80:732-738. [PMID: 37252708 PMCID: PMC10230371 DOI: 10.1001/jamaneurol.2023.1449] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Accepted: 03/31/2023] [Indexed: 05/31/2023]
Abstract
Importance Symptomatic intracranial hemorrhage (sICH) is a serious complication of stroke thrombolytic therapy. Many stroke centers have adopted 0.25-mg/kg tenecteplase instead of alteplase for stroke thrombolysis based on evidence from randomized comparisons to alteplase as well as for its practical advantages. There have been no significant differences in symptomatic intracranial hemorrhage (sICH) reported from randomized clinical trials or published case series for the 0.25-mg/Kg dose. Objective To assess the risk of sICH following ischemic stroke in patients treated with tenecteplase compared to those treated with alteplase. Design, Setting, and Participants This was a retrospective observational study using data from the large multicenter international Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) collaboration comprising deidentified data on patients with ischemic stroke treated with intravenous thrombolysis. Data from more than 100 hospitals in New Zealand, Australia, and the US that used alteplase or tenecteplase for patients treated between July 1, 2018, and June 30, 2021, were included for analysis. Participating centers included a mix of nonthrombectomy- and thrombectomy-capacity comprehensive stroke centers. Standardized data were abstracted and harmonized from local or regional clinical registries. Consecutive patients with acute ischemic stroke who were considered eligible and received thrombolysis at the participating stroke registries during the study period were included. All 9238 patients who received thrombolysis were included in this retrospective analysis. Main Outcomes and Measures sICH was defined as clinical worsening of at least 4 points on the National Institutes of Health Stroke Scale (NIHSS), attributed to parenchymal hematoma, subarachnoid, or intraventricular hemorrhage. Differences between tenecteplase and alteplase in the risk of sICH were assessed using logistic regression, adjusted for age, sex, NIHSS score, and thrombectomy. Results Of the 9238 patients included in the analysis, the median (IQR) age was 71 (59-80) years, and 4449 patients (48%) were female. Tenecteplase was administered to 1925 patients. The tenecteplase group was older (median [IQR], 73 [61-81] years vs 70 [58-80] years; P < .001), more likely to be male (1034 of 7313 [54%] vs 3755 of 1925 [51%]; P < .01), had higher NIHSS scores (median [IQR], 9 [5-17] vs 7 [4-14]; P < .001), and more frequently underwent endovascular thrombectomy (38% vs 20%; P < .001). The proportion of patients with sICH was 1.8% for tenecteplase and 3.6% for alteplase (P < .001), with an adjusted odds ratio (aOR) of 0.42 (95% CI, 0.30-0.58; P < .01). Similar results were observed in both thrombectomy and nonthrombectomy subgroups. Conclusions and Relevance In this large study, ischemic stroke treatment with 0.25-mg/kg tenecteplase was associated with lower odds of sICH than treatment with alteplase. The results provide evidence supporting the safety of tenecteplase for stroke thrombolysis in real-world clinical practice.
Collapse
Affiliation(s)
- Steven J. Warach
- Department of Neurology, Dell Medical School, University of Texas at Austin, Austin
- Ascension Texas, Austin
| | - Anna Ranta
- Department of Medicine, University of Otago, Wellington, New Zealand
- Department of Neurology, Wellington Hospital, Wellington, New Zealand
| | - Joosup Kim
- Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
| | - Shlee S. Song
- Department of Neurology, Cedars Sinai Medical Center, Los Angeles, California
- Department of Neurology, Torrance Memorial Medical Centre, Torrance, California
- Department of Neurology, Cedars Sinai Marina Del Rey Hospital, Marina del Rey, California
| | | | - James Beharry
- Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
- Department of Neurology, Christchurch Hospital, Christchurch, New Zealand
| | | | - Dominique A. Cadilhac
- Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
| | - Christopher F. Bladin
- Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia
- Ambulance Victoria, Melbourne, Victoria, Australia
| | - Timothy J. Kleinig
- Department of Neurology. Royal Adelaide Hospital, Adelaide, South Australia, Australia
| | - Jackson Harvey
- Department of Neurology. Royal Adelaide Hospital, Adelaide, South Australia, Australia
| | - Logesh Palanikumar
- Department of Neurology. Royal Adelaide Hospital, Adelaide, South Australia, Australia
| | - Vinodh T. Doss
- Department of Neurology, Novant Health - New Hanover Regional Medical Center, Wilmington, North Carolina
| | - Ruth Marescalco
- Department of Neurology, Novant Health - New Hanover Regional Medical Center, Wilmington, North Carolina
| | - John N. Fink
- Department of Neurology, Christchurch Hospital, Christchurch, New Zealand
| | - Alicia Tyson
- Department of Neurology, Wellington Hospital, Wellington, New Zealand
| | - Konrad H. Schlick
- Department of Neurology, Cedars Sinai Medical Center, Los Angeles, California
| | - Lydia Noh
- Department of Neurology, Cedars Sinai Medical Center, Los Angeles, California
| | - Duncan Wilson
- Department of Neurology, Christchurch Hospital, Christchurch, New Zealand
| | - Sonia Figueroa
- Department of Neurology, Cedars Sinai Medical Center, Los Angeles, California
| | - Marco A. Pech
- Department of Neurology, Torrance Memorial Medical Centre, Torrance, California
| | - Laurie B. Paletz
- Department of Neurology, Cedars Sinai Medical Center, Los Angeles, California
| | - Maya K. Lewis
- Department of Neurology, Cedars Sinai Marina Del Rey Hospital, Marina del Rey, California
| | - Marissa Castro
- Department of Neurology, Cedars Sinai Medical Center, Los Angeles, California
- Department of Neurology, Cedars Sinai Marina Del Rey Hospital, Marina del Rey, California
| | - Daniel H. Sahlein
- Goodman Campbell Brain and Spine, Indianapolis, Indiana
- Ascension St Vincent’s, Indianapolis, Indiana
| | | | | | | | | | | | | | | | | | - Bruce C. V. Campbell
- Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
| | - Teddy Y. Wu
- Department of Neurology, Christchurch Hospital, Christchurch, New Zealand
| |
Collapse
|
22
|
Sinclair JE, Plante M, Harrison MF, Sanghavi DK. ST-elevation myocardial infarction after thrombolytic therapy with Tenecteplase for acute ischaemic stroke. BMJ Case Rep 2023; 16:e252253. [PMID: 37316282 PMCID: PMC10277056 DOI: 10.1136/bcr-2022-252253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/16/2023] Open
Abstract
Myocardial infarction (MI) secondary to thrombolytic therapy in the setting of acute ischaemic stroke (AIS) is a rare but severe complication. This phenomenon has been well documented in the past with recombinant tissue-type plasminogen activator, also known as Alteplase. However, there are no documented reports of MI secondary to Tenecteplase (TNKase), an alternative thrombolytic agent rapidly gaining favour in managing AIS. We report a male patient in his 50s who received TNKase for an AIS and subsequently developed an inferolateral ST elevation MI.
Collapse
Affiliation(s)
- Jorge Enrique Sinclair
- Department of Critical Care Medicine, Mayo Clinic in Florida, Jacksonville, Florida, USA
| | - Marie Plante
- Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA
| | - Michael F Harrison
- Department of Emergency Medicine, Mayo Clinic, Jacksonville, Florida, USA
| | - Devang K Sanghavi
- Department of Critical Care Medicine, Mayo Clinic in Florida, Jacksonville, Florida, USA
| |
Collapse
|
23
|
Grotta JC. Intravenous Thrombolysis for Acute Ischemic Stroke. Continuum (Minneap Minn) 2023; 29:425-442. [PMID: 37039403 DOI: 10.1212/con.0000000000001207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
Abstract
OBJECTIVE This article reviews the history of IV thrombolysis, its current indications and implementation, the duality of the "time is brain" versus "tissue clock" approaches, the impact of endovascular thrombectomy on IV thrombolysis, the emergence of tenecteplase, and future research directions. LATEST DEVELOPMENTS The growing use of factor Xa inhibitors has increasingly caused patients with stroke to be excluded from treatment with IV thrombolysis. Important geographic, socioeconomic, sex, race, and ethnic disparities have been identified in the implementation of IV thrombolysis and need to be overcome. IV thrombolysis substantially improves outcomes when provided within the first golden hour after stroke onset in patients treated in mobile stroke units, supporting the "time is brain" concept and encouraging the possible value of more widespread implementation of the mobile stroke unit approach. At the same time, other studies have shown that IV thrombolysis can be successful in patients whose "tissue clock" is still ticking up to 9 hours after stroke onset or in patients who awaken with their stroke, as demonstrated by favorable imaging profiles. These considerations, along with the emergence of endovascular thrombectomy, have fostered examination of our care systems, including the "drip and ship" versus direct to comprehensive or endovascular thrombectomy stroke center approaches, as well as the possibility of skipping IV thrombolysis in certain patients treated with endovascular thrombectomy. Data suggesting that tenecteplase is at least noninferior to alteplase, as well as its more convenient dosing, has led to its increased use. Ongoing studies are evaluating newer thrombolytics and adding antithrombotic therapy to IV thrombolysis. ESSENTIAL POINTS IV thrombolysis remains the most common acute stroke treatment. Advances in acting faster to treat stroke have increased its efficacy, and advances in imaging have expanded its use. However, implementing these advances and overcoming disparities in IV thrombolysis use remain major challenges.
Collapse
|
24
|
Miller SE, Warach SJ. Evolving Thrombolytics: from Alteplase to Tenecteplase. Neurotherapeutics 2023; 20:664-678. [PMID: 37273127 PMCID: PMC10275840 DOI: 10.1007/s13311-023-01391-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/17/2023] [Indexed: 06/06/2023] Open
Abstract
Alteplase has been the primary thrombolytic used in the treatment of acute ischemic stroke since thrombolysis was first established as an effective treatment of acute ischemic stroke in 1995. Tenecteplase, a genetically modified tissue plasminogen activator, has gained attention as an attractive alternative to alteplase given its practical workflow advantages and possible superior efficacy in large vessel recanalization. As more data is analyzed both from randomized trials and non-randomized patient registries, there is mounting support that tenecteplase appears to be at least equally, if not more, safe and potentially more effective than alteplase in the treatment of acute ischemic stroke. Randomized trials investigating tenecteplase in the delayed treatment window and with thrombectomy are ongoing, and their results are eagerly awaited. This paper provides an overview of completed and ongoing randomized trials and nonrandomized studies analyzing tenecteplase in the treatment of acute ischemic stroke. Results reviewed support the safe use of tenecteplase in clinical practice.
Collapse
Affiliation(s)
- Samantha E Miller
- Department of Neurology, Dell Medical School, University of Texas at Austin, 1601 Trinity St., Bldg. B, Stop Z0700, Austin, TX, 78712, USA.
| | - Steven J Warach
- Department of Neurology, Dell Medical School, University of Texas at Austin, 1601 Trinity St., Bldg. B, Stop Z0700, Austin, TX, 78712, USA
| |
Collapse
|
25
|
Feasibility of switching from alteplase to tenecteplase for stroke thrombolysis – a retrospective cohort analysis. IBRO Neurosci Rep 2023; 14:353-357. [PMID: 37063607 PMCID: PMC10102389 DOI: 10.1016/j.ibneur.2023.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Accepted: 03/04/2023] [Indexed: 03/09/2023] Open
Abstract
Introduction Tenecteplase (TNK-tPA) has several benefits over alteplase (tPA) in treatment of acute ischaemic stroke. Randomised controlled trials have shown promising results. In June 2017, the Stroke Unit at Sundsvall County Hospital switched from tPA to TNK-tPA in standard clinical practice. This study examines the effects of that shift. Methods All thrombolysis treatments performed during the first twenty-four months with TNK-tPA (168) were compared to the last twenty-four months with tPA (191). Data were collected from patient records. Follow-up time was 30 days. Co-primary outcomes were death and symptomatic intracranial haemorrhage (SICH). Secondary outcomes were types of intracerebral bleeding and cause of death. Tertiary outcome was door-to-needle time (DNT). Results Treatment groups were of comparable age (75.7 ± 0.2 years). tPA-treated patients had an NIHSS (National Institutes of Health Stroke Scale) score of 9.2 versus 7.5 for TNK-tPA. Patients older than 80 had more severe strokes (median NIHSS 9 versus 5). SICH occurred in 6 (3.6 %) patients in the TNK-tPA group and in 2 (1.0 %) treated with tPA, odds ratio (OR) 3.41 (0.70-16.7). Numbers for death were 21 (12.5 %) and 31 (15.2 %), OR 0.77 (0.46-1.29), meaning no statistically significant differences in primary outcomes. There were no significant differences in secondary outcomes. Predominant cause of death was cerebral infarction. DNT with tenecteplase was shorter: mean 44 versus 26, and median 35 versus 19 min. Conclusions Switching from alteplase to tenecteplase was associated with shorter time to treatment. To draw certain conclusions regarding safety or efficacy would require a larger material.
Collapse
|
26
|
Alamowitch S, Turc G, Palaiodimou L, Bivard A, Cameron A, De Marchis GM, Fromm A, Kõrv J, Roaldsen MB, Katsanos AH, Tsivgoulis G. European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. Eur Stroke J 2023; 8:8-54. [PMID: 37021186 PMCID: PMC10069183 DOI: 10.1177/23969873221150022] [Citation(s) in RCA: 31] [Impact Index Per Article: 31.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 12/21/2022] [Indexed: 02/05/2023] Open
Abstract
Within the last year, four randomised-controlled clinical trials (RCTs) have been published comparing intravenous thrombolysis (IVT) with tenecteplase and alteplase in acute ischaemic stroke (AIS) patients with a non-inferiority design for three of them. An expedited recommendation process was initiated by the European Stroke Organisation (ESO) and conducted according to ESO standard operating procedure based on the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework. We identified three relevant Population, Intervention, Comparator, Outcome (PICO) questions, performed systematic reviews of the literature and meta-analyses, assessed the quality of the available evidence, and wrote evidence-based recommendations. Expert consensus statements were provided if insufficient evidence was available to provide recommendations based on the GRADE approach. For patients with AIS of <4.5 h duration who are eligible for IVT, tenecteplase 0.25 mg/kg can be used as a safe and effective alternative to alteplase 0.9 mg/kg (moderate evidence, strong recommendation). For patients with AIS of <4.5 h duration who are eligible for IVT, we recommend against using tenecteplase at a dose of 0.40 mg/kg (low evidence, strong recommendation). For patients with AIS of <4.5 h duration with prehospital management with a mobile stroke unit who are eligible for IVT, we suggest tenecteplase 0.25 mg/kg over alteplase 0.90 mg/kg (low evidence, weak recommendation). For patients with large vessel occlusion (LVO) AIS of <4.5 h duration who are eligible for IVT, we recommend tenecteplase 0.25 mg/kg over alteplase 0.9 mg/kg (moderate evidence, strong recommendation). For patients with AIS on awakening from sleep or AIS of unknown onset who are selected with non-contrast CT, we recommend against IVT with tenecteplase 0.25 mg/kg (low evidence, strong recommendation). Expert consensus statements are also provided. Tenecteplase 0.25 mg/kg may be favoured over alteplase 0.9 mg/kg for patients with AIS of <4.5 h duration in view of comparable safety and efficacy data and easier administration. For patients with LVO AIS of <4.5 h duration who are IVT-eligible, IVT with tenecteplase 0.25 mg/kg is preferable over skipping IVT before MT, even in the setting of a direct admission to a thrombectomy-capable centre. IVT with tenecteplase 0.25 mg/kg may be a reasonable alternative to alteplase 0.9 mg/kg for patients with AIS on awakening from sleep or AIS of unknown onset and who are IVT-eligible after selection with advanced imaging.
Collapse
Affiliation(s)
- Sonia Alamowitch
- AP-HP, Service des Urgences Cérébro-Vasculaires, Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, STARE team, iCRIN, Institut du Cerveau, Sorbonne Université, Paris, France
| | - Guillaume Turc
- Department of Neurology, GHU Paris Psychiatrie et Neurosciences, Paris, France
- Université Paris Cité, Paris, France
- INSERM U1266, Paris, France
- FHU NeuroVasc, Paris, France
| | - Lina Palaiodimou
- Second Department of Neurology, School of Medicine, National & Kapodistrian University of Athens, ‘Attikon’ University Hospital, Athens, Greece
| | - Andrew Bivard
- Melbourne Brain Centre, University of Melbourne, Melbourne, Australia
| | - Alan Cameron
- School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK
| | - Gian Marco De Marchis
- Department of Neurology & Stroke Center, University Hospital Basel, Switzerland
- Department of Clinical Research, University of Basel, Switzerland
| | - Annette Fromm
- Department of Neurology, Center for Neurovascular Diseases, Haukeland University Hospital, Bergen, Norway
| | - Janika Kõrv
- Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia
| | - Melinda B Roaldsen
- Department of Clinical Research, University Hospital of North Norway, Tromsø, Norway
| | - Aristeidis H Katsanos
- Division of Neurology, McMaster University and Population Health Research Institute, Hamilton, ON, Canada
| | - Georgios Tsivgoulis
- Second Department of Neurology, School of Medicine, National & Kapodistrian University of Athens, ‘Attikon’ University Hospital, Athens, Greece
| |
Collapse
|
27
|
Rehman AU, Mohsin A, Cheema HA, Zahid A, Ebaad Ur Rehman M, Ameer MZ, Ayyan M, Ehsan M, Shahid A, Aemaz Ur Rehman M, Shah J, Khawaja A. Comparative efficacy and safety of tenecteplase and alteplase in acute ischemic stroke: A pairwise and network meta-analysis of randomized controlled trials. J Neurol Sci 2023; 445:120537. [PMID: 36630803 DOI: 10.1016/j.jns.2022.120537] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2022] [Revised: 12/04/2022] [Accepted: 12/26/2022] [Indexed: 12/31/2022]
Abstract
BACKGROUND Studies on tenecteplase have been yielding mixed results for several important outcomes at different doses, thus hampering objective guideline recommendations in acute ischemic stroke management. This meta-analysis stratifies doses in order to refine our interpretation of outcomes and quantify the benefits and harms of tenecteplase at different doses. METHODS PubMed/MEDLINE, the Cochrane Library, and reference lists of the included articles were systematically searched. Several efficacy and safety outcomes were pooled and reported as risk ratios (RRs) with 95% confidence intervals (CIs). Network meta-analysis was used to find the optimal dose of tenecteplase. Meta-regression was run to investigate the impact of baseline NIHSS scores on functional outcomes and mortality. RESULTS Ten randomized controlled trials with a total of 4140 patients were included. 2166 (52.32%) patients were enrolled in the tenecteplase group and 1974 (47.68%) in the alteplase group. Tenecteplase at 0.25 mg/kg dose demonstrated significant improvement in excellent functional outcome at 3 months (RR 1.14, 95% CI 1.04-1.26), and early neurological improvement (RR 1.53, 95% CI 1.03-2.26). There was no statistically significant difference between tenecteplase and alteplase in terms of good functional outcome, intracerebral hemorrhage (ICH), symptomatic intracerebral hemorrhage (sICH), and 90-day mortality at any dose. Meta-regression demonstrated superior tenecteplase efficacy with increasing stroke severity, however, the results were statistically nonsignificant. CONCLUSIONS Tenecteplase at 0.25 mg/kg dose is more efficacious and at least as safe as alteplase for stroke thrombolysis. Newer analyses need to focus on direct comparison of tenecteplase doses and whether tenecteplase is efficacious at longer needle times.
Collapse
Affiliation(s)
- Aqeeb Ur Rehman
- Department of Neurology, King Edward Medical University, Lahore, Pakistan
| | - Aleenah Mohsin
- Department of Neurology, King Edward Medical University, Lahore, Pakistan
| | | | - Afra Zahid
- Department of Neurology, King Edward Medical University, Lahore, Pakistan
| | | | | | - Muhammad Ayyan
- Department of Neurology, King Edward Medical University, Lahore, Pakistan
| | - Muhammad Ehsan
- Department of Neurology, King Edward Medical University, Lahore, Pakistan
| | - Abia Shahid
- Department of Neurology, King Edward Medical University, Lahore, Pakistan.
| | - Muhammad Aemaz Ur Rehman
- Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Jaffer Shah
- New York State Department of Health, Albany, NY, USA
| | - Ayaz Khawaja
- Department of Neurology, Wayne State University-Detroit Medical Center, Detroit, MI, USA
| |
Collapse
|
28
|
Abuelazm M, Seri AR, Awad AK, Ahmad U, Mahmoud A, Albazee E, Kambalapalli S, Abdelazeem B. The efficacy and safety of tenecteplase versus alteplase for acute ischemic stroke: an updated systematic review, pairwise, and network meta-analysis of randomized controlled trials. J Thromb Thrombolysis 2023; 55:322-338. [PMID: 36449231 PMCID: PMC10011306 DOI: 10.1007/s11239-022-02730-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 10/30/2022] [Indexed: 12/05/2022]
Abstract
Tenecteplase (TNK) is a promising candidate to replace alteplase as the standard of care for acute ischemic stroke (AIS); however, the optimal dosage is still to be investigated. Therefore, we aim to evaluate the safety and efficacy of TNK versus alteplase and to investigate the optimal TNK dosage. A systematic review, pairwise, and network meta-analysis synthesizing randomized controlled trials (RCTs) from WOS, SCOPUS, EMBASE, and PubMed until July 26th, 2022. We used the risk ratio (RR) for dichotomous outcomes presented with the corresponding 95% confidence interval (CI). We registered our protocol in PROSPERO with ID: CRD42022352038. Nine RCTs with a total of 3,707 patients were included. TNK significantly led to complete recanalization (RR: 1.27 with 95% CI [1.02, 1.57], P = 0.03); however, we found no difference regarding early neurological improvement (RR: 1.07 with 95% CI [0.94, 1.21], P = 0.33) and excellent neurological recovery (RR: 1.03 with 95% CI [0.96, 1.10], P = 0.42). Also, TNK was similar to alteplase regarding mortality (RR: 0.99 with 95% CI [0.82, 1.18], P = 0.88), intracranial haemorrhage (RR: 1.00 with 95% CI [0.85, 1.18], P = 0.99), and parenchymal hematoma (RR: 1.13 with 95% CI [0.83, 1.54], P = 0.44). TNK in the dose of 0.25 mg is a viable candidate to displace alteplase as the standard of care in patients with an AIS within 4.5 h of presentation due to its better rate of early neurological recovery and non-inferiority in terms of safety outcomes. However, the evidence regarding TNK's role in AIS presenting after 4.5 h from symptoms onset, wake-up stroke, and minor stroke/TIA is still lacking, necessitating further double-blinded pragmatic RCTs in this regard.
Collapse
Affiliation(s)
| | - Amith Reddy Seri
- Department of Internal Medicine, McLaren Health Care, Flint, MI USA
- Department of Internal Medicine, Michigan State University, East Lansing, MI USA
| | - Ahmed K. Awad
- Faculty of Medicine, Ain-Shams University, Cairo, Egypt
| | | | | | - Ebraheem Albazee
- Kuwait Institute for Medical Specializations (KIMS), Kuwait City, Kuwait
| | - Soumya Kambalapalli
- Department of Internal Medicine, McLaren Health Care, Flint, MI USA
- Department of Internal Medicine, Michigan State University, East Lansing, MI USA
| | - Basel Abdelazeem
- Department of Internal Medicine, McLaren Health Care, Flint, MI USA
- Department of Internal Medicine, Michigan State University, East Lansing, MI USA
| |
Collapse
|
29
|
Leys D, Mas JL. Quelles pistes d’avenir pour le traitement de l’infarctus cérébral aigu ? BULLETIN DE L'ACADÉMIE NATIONALE DE MÉDECINE 2023. [DOI: 10.1016/j.banm.2022.10.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
30
|
Zhao ZA, Qiu J, Wang L, Zhao YG, Sun XH, Li W, Liu X, Li XL, Liu L, Chen MR, Chen HS. Intra-arterial tenecteplase is safe and may improve the first-pass recanalization for acute ischemic stroke with large-artery atherosclerosis: the BRETIS-TNK trial. Front Neurol 2023; 14:1155269. [PMID: 37143999 PMCID: PMC10151652 DOI: 10.3389/fneur.2023.1155269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Accepted: 04/03/2023] [Indexed: 05/06/2023] Open
Abstract
Background and purpose The first-pass recanalization of endovascular treatment (EVT) is closely correlated with clinical outcome of patients with large vessel occlusion (LVO) stroke. The aim of the study was to explore whether intra-arterial tenecteplase (TNK) during the first pass of EVT can increase first-pass successful reperfusion and improve the neurological outcome in AIS-LVO patients. Materials and methods The BRETIS-TNK trial (ClinicalTrials.gov Identifier: NCT04202458) was a prospective, single-arm, single center study. Twenty-six eligible AIS-LVO patients with large-artery atherosclerosis etiology were consecutively enrolled from December 2019 to November 2021. Intra-arterial TNK (4 mg) after microcatheter navigation through the clot was administered, followed by TNK (0.4 mg/min) given continuously for 20 min after the first retrieval attempt of EVT without confirmation of the reperfusion status by DSA. The 50 control patients comprised of a historical cohort before the BRETIS-TNK trial (from March 2015 to November 2019). Successful reperfusion was defined as modified Thrombolysis In Cerebral Infarction (mTICI) ≥2b. Results The first-pass successful reperfusion rate was higher in the BRETIS-TNK vs. control group (53.8% vs. 36%, p = 0.14), and the difference became statistically significant after propensity score matching (53.8% vs. 23.1%, p = 0.03). There was no difference in symptomatic intracranial hemorrhage between the BRETIS-TNK and control groups (7.7% vs. 10.0%, p = 0.92). There was a trend toward higher proportion of functional independence at 90 days in the BRETIS-TNK comparing with the control group (50% vs. 32%, p = 0.11). Conclusion This is the first study to report that intra-arterial TNK during the first pass of EVT seems safe and feasible in AIS-LVO patients.
Collapse
|
31
|
Singh N, Menon BK, Dmytriw AA, Regenhardt RW, Hirsch JA, Ganesh A. Replacing Alteplase with Tenecteplase: Is the Time Ripe? J Stroke 2023; 25:72-80. [PMID: 36746381 PMCID: PMC9911848 DOI: 10.5853/jos.2022.02880] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Accepted: 12/15/2022] [Indexed: 02/04/2023] Open
Abstract
Thrombolysis for acute ischemic stroke has predominantly been with alteplase for over a quarter of a century. In recent years, with trials showing evidence of higher rates of successful reperfusion, similar safety profile and efficacy of tenecteplase (TNK) as compared to alteplase, TNK has now emerged as another potential choice for thrombolysis in acute ischemic stroke. In this review, we will focus on these recent advances, aiming: (1) to provide a brief overview of thrombolysis in stroke; (2) to provide comparisons between alteplase and TNK for clinical, imaging, and safety outcomes; (3) to focus on key subgroups of interest to understand if there is an advantage of using TNK over alteplase or vice-versa, to review available evidence on role of TNK in intra-arterial thrombolysis, as bridging therapy and in mobile stroke units; and (4) to summarize what to expect in the near future from recently completed trials and propose areas for future research on this evolving topic. We present compelling data from several trials regarding the safety and efficacy of TNK in acute ischemic stroke along with completed yet unpublished trials that will help provide insight into these unanswered questions.
Collapse
Affiliation(s)
- Nishita Singh
- Calgary Stroke Program, Departments of Clinical Neurosciences, Radiology, and Community Health Sciences, and the Hotchkiss Brain Institute, University of Calgary Cumming School of Medicine, Calgary, AB, Canada,Department of Internal Medicine-Neurology Division, Health Sciences Center, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
| | - Bijoy K. Menon
- Calgary Stroke Program, Departments of Clinical Neurosciences, Radiology, and Community Health Sciences, and the Hotchkiss Brain Institute, University of Calgary Cumming School of Medicine, Calgary, AB, Canada
| | - Adam A. Dmytriw
- Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA,Neuroendovascular Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Robert W. Regenhardt
- Neuroendovascular Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Joshua A. Hirsch
- Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Aravind Ganesh
- Calgary Stroke Program, Departments of Clinical Neurosciences, Radiology, and Community Health Sciences, and the Hotchkiss Brain Institute, University of Calgary Cumming School of Medicine, Calgary, AB, Canada,Correspondence: Aravind Ganesh Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, HMRB 103, Heritage Medical Research Building, 3280 Hospital Dr. NW, Calgary, Alberta T2N 4Z6, Canada Tel: +1-403-220-3747 E-mail:
| |
Collapse
|
32
|
Hajian K, Abdi Dezfouli R, Darvishi A, Radmanesh R, Heshmat R. Tenecteplase in managing acute ischemic stroke: a long-term cost-utility analysis in Iran. Expert Rev Pharmacoecon Outcomes Res 2023; 23:123-133. [PMID: 36420792 DOI: 10.1080/14737167.2023.2152008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND & AIMS The advantage of tenecteplase (TNK) over alteplase (ALT) in managing acute ischemic stroke (AIS) has been reported, but the cost-effectiveness of these two strategies has not received as much attention. The objective of this study was to compare TNK and ALT for the management of AIS patients in Iran in terms of cost-effectiveness. METHODS This study was carried out from the payer's perspective in Iran, with a lifetime horizon. A full economic evaluation model was designed as a decision tree and a Markov model. After defining different Markov states, each health state was assigned a utility value, and quality-adjusted life year (QALY) was estimated using that value. The incremental cost-effectiveness ratio (ICER) was ultimately used for evaluating the comparative cost-effectiveness. Both deterministic and probabilistic sensitivity analyses were carried out. RESULTS Compared to ALT, TNK can save approximately 4333.81 USD, and is able to increase one unit of QALY while saving approximately 17,450.29 USD. So, Base-case results showed that TNK strongly dominates ALT. Moreover, the base case results were strongly confirmed by deterministic and probabilistic sensitivity analysis. CONCLUSIONS Base-case and sensitivity analysis showed that TNK is the dominant strategy compared to ALT for the management of AIS patients.
Collapse
Affiliation(s)
- Kosar Hajian
- Department of Pharmacoeconomics and Pharmaceutical Management, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.,Chronic Diseases Research Center, Endocrinology and Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Ramin Abdi Dezfouli
- Department of Pharmacoeconomics and Pharmaceutical Management, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.,Chronic Diseases Research Center, Endocrinology and Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Ali Darvishi
- Chronic Diseases Research Center, Endocrinology and Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.,Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences (TUMS), Tehran, Iran
| | - Ramin Radmanesh
- Department of Pharmacoeconomics and Pharmaceutical Management, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Ramin Heshmat
- Chronic Diseases Research Center, Endocrinology and Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
33
|
Gerschenfeld G, Liegey JS, Laborne FX, Yger M, Lyon V, Checkouri T, Tricard-Dessagne B, Marnat G, Clarençon F, Chausson N, Turc G, Sibon I, Alamowitch S, Olindo S. Treatment times, functional outcome, and hemorrhage rates after switching to tenecteplase for stroke thrombolysis: Insights from the TETRIS registry. Eur Stroke J 2022; 7:358-364. [PMID: 36478758 PMCID: PMC9720850 DOI: 10.1177/23969873221113729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Accepted: 06/27/2022] [Indexed: 02/25/2024] Open
Abstract
INTRODUCTION The encouraging efficacy and safety data on intravenous thrombolysis with tenecteplase in ischemic stroke and its practical advantages motivated our centers to switch from alteplase to tenecteplase. We report its impact on treatment times and clinical outcomes. METHODS We retrospectively analyzed clinical and procedural data of patients treated with alteplase or tenecteplase in a comprehensive (CSC) and a primary stroke center (PSC), which transitioned respectively in 2019 and 2018. Tenecteplase enabled in-imaging thrombolysis in the CSC. The main outcomes were the imaging-to-thrombolysis and thrombolysis-to-puncture times. We assessed the association of tenecteplase with 3-month functional independence and parenchymal hemorrhage (PH) with multivariable logistic models. RESULTS We included 795 patients, 387 (48.7%) received alteplase and 408 (51.3%) tenecteplase. Both groups (tenecteplase vs alteplase) were similar in terms of age (75 vs 76 years), baseline NIHSS score (7 vs 7.5) and proportion of patients treated with mechanical thrombectomy (24.1% vs 27.5%). Tenecteplase patients had shorter imaging-to-thrombolysis times (27 vs 36 min, p < 0.0001) mainly driven by patients treated in the CSC (22 vs 38 min, p < 0.001). In the PSC, tenecteplase patients had shorter thrombolysis-to-puncture times (84 vs 95 min, p = 0.02), reflecting faster interhospital transfer for MT. 3-month functional independence rate was higher in the tenecteplase group (62.8% vs 53.4%, p < 0.01). In the multivariable analysis, tenecteplase was significantly associated with functional independence (ORa 1.68, 95% CI 1.15-2.48, p < 0.01), but not with PH (ORa 0.68, 95% CI 0.41-1.12, p = 0.13). CONCLUSION Switch from alteplase to tenecteplase reduced process times and may improve functional outcome, with similar safety profile.
Collapse
Affiliation(s)
- Gaspard Gerschenfeld
- AP-HP, Service des Urgences
Cérébro-Vasculaires, Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, Sorbonne
Université, Paris, France
- STARE Team, iCRIN, Institut du Cerveau
et de la Moelle épinière, ICM, Paris, France
| | | | | | - Marion Yger
- AP-HP, Service des Urgences
Cérébro-Vasculaires, Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, Sorbonne
Université, Paris, France
- STARE Team, iCRIN, Institut du Cerveau
et de la Moelle épinière, ICM, Paris, France
| | - Victoire Lyon
- Service de Neurologie Vasculaire, CHU
de Bordeaux, Bordeaux, France
| | - Thomas Checkouri
- AP-HP, Service des Urgences
Cérébro-Vasculaires, Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, Sorbonne
Université, Paris, France
- STARE Team, iCRIN, Institut du Cerveau
et de la Moelle épinière, ICM, Paris, France
| | | | - Gaultier Marnat
- Service de Neuroradiologie diagnostique
et interventionnelle, CHU de Bordeaux, Bordeaux, France
| | - Frédéric Clarençon
- AP-HP, Service de Neuroradiologie,
Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France
| | - Nicolas Chausson
- Service de Neurologie, Unité
Neuro-vasculaire, Hôpital Sud Francilien, Corbeil-Essonnes, France
| | - Guillaume Turc
- Service de Neurologie, GHU Paris
Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc,
Paris, France
| | - Igor Sibon
- Service de Neurologie Vasculaire, CHU
de Bordeaux, Bordeaux, France
| | - Sonia Alamowitch
- AP-HP, Service des Urgences
Cérébro-Vasculaires, Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, Sorbonne
Université, Paris, France
- STARE Team, iCRIN, Institut du Cerveau
et de la Moelle épinière, ICM, Paris, France
- CRSA, Sorbonne Université, INSERM, UMRS
938, Hôpital Saint-Antoine, Paris, France
| | - Stéphane Olindo
- Service de Neurologie Vasculaire, CHU
de Bordeaux, Bordeaux, France
| |
Collapse
|
34
|
Wang X, Ye Z, Busse JW, Hill MD, Smith EE, Guyatt GH, Prasad K, Lindsay MP, Yang H, Zhang Y, Liu Y, Tang B, Wang X, Wang Y, Couban RJ, An Z. Endovascular thrombectomy with or without intravenous alteplase for acute ischemic stroke due to large vessel occlusion: a systematic review and meta-analysis of randomized trials. Stroke Vasc Neurol 2022; 7:510-517. [PMID: 35725244 PMCID: PMC9811536 DOI: 10.1136/svn-2022-001547] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Accepted: 05/23/2022] [Indexed: 01/28/2023] Open
Abstract
BACKGROUND Among patients who had an ischaemic stroke presenting directly to a stroke centre where endovascular thrombectomy (EVT) is immediately available, there is uncertainty regarding the role of intravenous thrombolysis agents before or concurrently with EVT. To support a rapid guideline, we conducted a systematic review and meta-analysis to examine the impact of EVT alone versus EVT with intravenous alteplase in patients who had an acute ischaemic stroke due to large vessel occlusion. METHODS In November 2021, we searched MEDLINE, Embase, PubMed, Cochrane, Web of Science, clincialtrials.gov and the ISRCTN registry for randomised controlled trials (RCTs) comparing EVT alone versus EVT with alteplase for acute ischaemic stroke. We conducted meta-analyses using fixed effects models and assessed the certainty of evidence using the GRADE approach. RESULTS In total 6 RCTs including 2334 participants were eligible. Low certainty evidence suggests that, compared with EVT and alteplase, there is possibly a small decrease in the proportion of patients independent with EVT alone (risk ratio (RR) 0.97, 95% CI 0.89 to 1.05; risk difference (RD) -1.5%; 95% CI -5.4% to 2.5%), and possibly a small increase in mortality with EVT alone (RR 1.07, 95% CI 0.88 to 1.29; RD 1.2%, 95% CI -2.0% to 4.9%) . Moderate certainty evidence suggests that there is probably a small decrease in symptomatic intracranial haemorrhage (sICH) with EVT alone (RR 0.75, 95% CI 0.52 to 1.07; RD -1.0%; 95%CI -1.8% to 0.27%). CONCLUSIONS Low certainty evidence suggests that there is possibly a small decrease in the proportion of patients that achieve functional independence and a small increase in mortality with EVT alone. Moderate certainty evidence suggests that there is probably a small decrease in sICH with EVT alone. The accompanying guideline provides contextualised guidance based on this body of evidence. PROSPERO REGISTRATION NUMBER CRD42021249873.
Collapse
Affiliation(s)
- Xin Wang
- Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
| | - Zhikang Ye
- Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
- Michael G DeGroote National Pain Centre, McMaster University, Hamilton, Ontario, Canada
| | - Jason W Busse
- Michael G DeGroote National Pain Centre, McMaster University, Hamilton, Ontario, Canada
- Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
- Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada
| | - Michael D Hill
- Department of Clinical Neurosciences and Hotchkiss Brain Institute, Departments of Medicine, Community Health Sciences and Radiology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
| | - Eric E Smith
- Department of Clinical Neurosciences and Calgary Stroke Program, University of Calgary, Calgary, Alberta, Canada
| | - Gordon H Guyatt
- Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
| | - Kameshwar Prasad
- Professor of neurology and Director, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India
| | | | - Hui Yang
- Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
| | - Yi Zhang
- Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
- Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China
| | - Ying Liu
- Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
| | - Borui Tang
- Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
| | - Xinrui Wang
- Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
- Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China
| | - Yushu Wang
- Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
- Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China
| | - Rachel J Couban
- DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, Ontario, Canada
| | - Zhuoling An
- Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
| |
Collapse
|
35
|
The EZ, Lin NN, Matar M, Teoh HL, Yeo LLL. Different dosing regimens of Tenecteplase in acute ischemic stroke: A network meta-analysis of the clinical evidence. Eur Stroke J 2022; 8:93-105. [PMID: 37021171 PMCID: PMC10069195 DOI: 10.1177/23969873221129924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Accepted: 09/13/2022] [Indexed: 11/15/2022] Open
Abstract
Introduction: Acute ischemic stroke remains the major cause of death and disability and conclusive evidence of Tenecteplase in treating stroke is lacking. Objective: To conduct a meta-analysis to determine whether Tenecteplase produces better outcomes than Alteplase and a network meta-analysis comparing the different dosing regimens of Tenecteplase. Methods: Searches were made in MEDLINE, CENTRAL, and ClinicalTrials.gov. The outcome measures are recanalization, early neurological improvement, functional outcomes at 90 days (modified Rankin Scale 0–1 and 0–2), intracranial hemorrhage, symptomatic intracranial hemorrhage, and mortality within 90 days from treatment. Results: Fourteen studies are included in the meta-analyses and 18 studies in the network meta-analyses. In the meta-analysis, Tenecteplase 0.25 mg/kg has significant results in early neurological improvement (OR = 2.35, and 95% CI = 1.16–4.72) and excellent functional outcome (OR = 1.20, and 95% CI = 1.02–1.42). In the network meta-analysis, Tenecteplase 0.25 mg/kg produces significant results in early neurological improvement (OR = 1.52 [95% CI = 1.13–2.05], p-value = 0.01), functional outcomes (mRS 0–1 and 0–2) (OR = 1.19 [95% CI = 1.03–1.37], p-value = 0.02; OR = 1.21 [95% CI = 1.05–1.39], p-value = 0.01; respectively) and mortality (OR = 0.78 [95% CI = 0.64–0.96], p-value = 0.02) whereas Tenecteplase 0.40 mg/kg increases the chances of symptomatic intracranial hemorrhage (OR = 2.35 [95% CI = 1.19–4.64], p-value = 0.01). Conclusion: While not conclusive, our study lends evidence to 0.25 mg/kg Tenecteplase dose for ischemic stroke treatment. Further randomized trials need to be done to validate this finding. Registration: International prospective register of systematic reviews (PROSPERO) – CRD42022339774 URL: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=339774
Collapse
Affiliation(s)
- Ei Zune The
- University Hospitals of Leicester NHS Trust, Leicester, UK
| | | | - Mazen Matar
- University Hospitals of Leicester NHS Trust, Leicester, UK
| | - Hock Luen Teoh
- Division of Neurology, Department of Medicine, National University Hospital, Singapore
| | | |
Collapse
|
36
|
The promise of tenecteplase in acute stroke: Within reach or beyond approval? MED 2022; 3:651-655. [DOI: 10.1016/j.medj.2022.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
37
|
Estella Á, Pérez Ruiz M, Serrano JJ. Effectiveness and Safety of Tecneplase vs. Alteplase in the Acute Treatment of Ischemic Stroke. J Pers Med 2022; 12:jpm12091525. [PMID: 36143310 PMCID: PMC9503588 DOI: 10.3390/jpm12091525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Revised: 09/15/2022] [Accepted: 09/15/2022] [Indexed: 11/16/2022] Open
Abstract
Not all hospitals have interventional radiology services. This fact implies that in centers where this resource is not available, the treatment of stroke in the acute phase must be adapted and individualized. The aim of the study is to determine and compare the combined effect of thrombolysis and thrombectomy effectiveness and safety of tenecteplase versus alteplase in the acute treatment of ischemic stroke in patients who are candidates for endovascular therapy according to clinical practice guidelines. This paper details a retrospective multicenter cohort study of patients with ischemic stroke admitted in three hospitals between 2018 and 2020. The main outcome variables were the degree of recanalization and the functional outcome at 3 months; safety variables were mortality and the occurrence of intracranial hemorrhage (ICH). In total, 100 patients were included, 20 of which were treated with tenecteplase (TNK) and 80 with alteplase (rtPA). Of those treated with TNK, 75% obtained a successful recanalization compared to 83.8% in those treated with rtPA (OR 0.58; 95% CI 0.18–1.88; p = 0.56). No differences were found in obtaining an excellent functional result at 3 months (35% TNK vs. 58.8% rtPA; p = 0.38). Tenecteplase showed worse neurological results after 24 h (unfavorable result of 70% with TNK vs. 45% with rtPA; OR = 5.4; 95% CI 1.57–18.6). No significant differences were identified in mortality; 17.5% with rtPA and 20% with TNK (p = 0.79), nor in the appearance of intracranial hemorrhage ICH (15.2% with rtPA vs. 30% with TNK (p = 0.12). In our series, there were not significant differences shown regarding effectiveness and safety between tenecteplase and alteplase.
Collapse
Affiliation(s)
- Ángel Estella
- Intensive Care Unit, University Hospital of Jerez, Medicine Department, University of Cádiz, 11407 Jerez, Spain
- Correspondence: ; Tel.: +34-956032090
| | - Miriam Pérez Ruiz
- Intensive Care Unit, University Hospital of Puerto Real, 11510 Puerto Real, Spain
| | | |
Collapse
|
38
|
Tenecteplase or Alteplase Better in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion: A Single Center Observational Study. MEDICINA (KAUNAS, LITHUANIA) 2022; 58:medicina58091169. [PMID: 36143846 PMCID: PMC9500675 DOI: 10.3390/medicina58091169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 08/19/2022] [Accepted: 08/22/2022] [Indexed: 11/23/2022]
Abstract
Background and Objectives: The study aimed to investigate the efficacy of intravenous thrombolysis with Tenecteplase before thrombectomy for acute ischemic stroke (AIS) patients compared with previous results using Alteplase. Previous trials for Tenecteplase have indicated an increased incidence of vascular reperfusion. In April 2021, we started to primarily give Tenecteplase to patients eligible to undergo thrombectomy. Materials and Methods: In this retrospective observational single-center non-randomized study, we analyzed directly admitted patients with AIS who had occlusion of the internal carotid, middle cerebral, or basilar artery and who underwent thrombectomy, as well as the recanalization rate for these patients at the first angiographic assessment (mTICI score 2b–3), and complications. Results: We included 184 patients (demographic characteristics did not differ between Tenecteplase and Alteplase groups (mean age 68.4 vs. 73.0 years; female sex 53.3% vs. 51.1%, NIHSS 14 (IQR 4–26) vs. 15 (2–31). Forty-five patients received Tenecteplase and 139 Alteplase before endovascular treatment (EVT). Pre-EVT (endovascular treatment) recanalization was more likely to occur with Tenecteplase rather than Alteplase (22.2% vs. 8.6%, p = 0.02). Successful reperfusion (mTICI 2b–3) after EVT was achieved in 155 patients (42 (93.4%) vs. 113 (81.3), p = 0.07). Hemorrhagic imbibition occurred in 15 (33.3%) Tenecteplase-treated patients compared with 39 (28.1%) Alteplase-treated patients (p = 0.5). Patients treated with Tenecteplase had higher odds of excellent functional outcome than Alteplase-treated patients (Tenecteplase 48.6% vs. Alteplase 26.1%; OR 0.37 (95% CI 0.17–0.81), p = 0.01). Conclusions: Tenecteplase (25 mg/kg) could have superior clinical efficacy over Alteplase for AIS patients with large-vessel occlusion (LVO), administered before EVT. The improvement in reperfusion rate and the better excellent functional outcome could come without an increased safety concern.
Collapse
|
39
|
Walton MN, Hamilton LA, Salyer S, Wiseman BF, Forster AM, Rowe AS. Major Bleeding Postadministration of Tenecteplase Versus Alteplase in Acute Ischemic Stroke. Ann Pharmacother 2022; 57:535-543. [PMID: 36004394 DOI: 10.1177/10600280221120211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Tenecteplase is a genetically engineered fibrinolytic with growing interest in the treatment of acute ischemic stroke. Compared to alteplase, tenecteplase is effective for neurologic improvement following ischemic stroke in patients with large vessel occlusions who are eligible for thrombectomy and for mild ischemic strokes with National Institutes of Health Stroke Scale of 0 to 5. OBJECTIVE The purpose of this study is to determine if safety outcomes are different in patients receiving tenecteplase and alteplase for acute ischemic stroke. METHODS This retrospective cohort reviewed all patients who received alteplase or tenecteplase from January 2019 to December 2020. Patients admitted before April 28, 2020, received alteplase intravenous bolus over 1 minute followed by an infusion over 1 hour, for a total of 0.9 mg/kg. Patients admitted after this date received tenecteplase 0.25 mg/kg as an intravenous bolus over 5 to 10 seconds. Any patient transferring from an outside facility was excluded. The primary outcome was major bleeding. RESULTS There was no significant difference in major bleeding between alteplase and tenecteplase (40 [18%] vs 21 [18.1%], P = 0.985). There was no significant difference in all-cause inpatient mortality for alteplase versus tenecteplase (10 [5%] vs 5 [4%], P = 0.934) or in adverse events between the groups (22 [9%] vs 14 [12%], P = 0.541) for alteplase and tenecteplase, respectively. CONCLUSIONS AND RELEVANCE Tenecteplase had similar rates of major bleeding versus alteplase and may be a reasonable alternative in the treatment of acute ischemic stroke.
Collapse
Affiliation(s)
- Mary N Walton
- Department of Pharmacy, University of Tennessee Medical Center, Knoxville, TN, USA.,Department of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center College of Pharmacy, Knoxville, TN, USA
| | - Leslie A Hamilton
- Department of Pharmacy, University of Tennessee Medical Center, Knoxville, TN, USA.,Department of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center College of Pharmacy, Knoxville, TN, USA
| | - Sonia Salyer
- Department of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center College of Pharmacy, Knoxville, TN, USA
| | - Brian F Wiseman
- Brain and Spine Institute, University of Tennessee Medical Center, Knoxville, TN, USA
| | - Ann M Forster
- Brain and Spine Institute, University of Tennessee Medical Center, Knoxville, TN, USA
| | - A Shaun Rowe
- Department of Pharmacy, University of Tennessee Medical Center, Knoxville, TN, USA.,Department of Clinical Pharmacy and Translational Science, University of Tennessee Health Science Center College of Pharmacy, Knoxville, TN, USA
| |
Collapse
|
40
|
Requiao LE, Oliveira RS, Reis LS, B Assis AP, G Moreno BN, Cordeiro LR, Solla DF. Short-Term Efficacy Outcomes of Tenecteplase versus Alteplase for Acute Ischemic Stroke: A Meta-Analysis of 5 Randomized Trials. Neurol India 2022; 70:1454-1459. [PMID: 36076643 DOI: 10.4103/0028-3886.355108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Tenecteplase (TNK) has been shown to be noninferior to Alteplase (ALT) for long term efficacy and safety outcomes. Whether this also applies to short term efficacy outcomes such as early clinical improvement and recanalization is unknown. To compare TNK and ALT regarding the short term efficacy outcomes: early neurological improvement and recanalization. The PRISMA was used to conduct a meta analysis, adapted to noninferiority analysis. The primary outcome was early (24-72 h) neurological improvement, defined as either NIHSS score 0 or reduction of at least 8 points compared to baseline. Recanalization was a secondary outcome. The noninferiority margin was set at 6.5%. Search strategy yielded 5 randomized clinical trials (1585 patients: 828 TNK, 757 ALT). Mean age was 70.8, 58.8% were men, mean baseline NIHSS was 7, and mean onset to treatment time was 148 min. Patients in intervention group received TNK at doses of 0.1 mg/kg (6.8%), 0.25 mg/kg (24.6%), and 0.4 mg/kg (68.6%), while all ALT patients received 0.9 mg/kg. In random effects meta analysis, TNK was noninferior to ALT for the primary outcome, early major neurological improvement (risk difference 8% in favor of TNK, 95% CI 1%-15%). Recanalization was also noninferior for the TNK compared to the ALT group (risk difference 9% in favor of TNK, 95% CI 6% to 23%). Fixed effects models yielded similarly noninferior results and signaled for a possible TNK superiority for both early neurological improvement and recanalization. TNK is noninferior to ALT at the short term efficacy outcomes: early neurological improvement and recanalization.
Collapse
Affiliation(s)
- Leticia E Requiao
- Bahiana School of Medicine and Public Health, Salvador, Bahia, Brazil
| | | | - Lorena S Reis
- Bahiana School of Medicine and Public Health, Salvador, Bahia, Brazil
| | - Ana P B Assis
- Bahiana School of Medicine and Public Health, Salvador, Bahia, Brazil
| | | | - Luisa R Cordeiro
- Bahiana School of Medicine and Public Health, Salvador, Bahia, Brazil
| | - Davi F Solla
- Division of Neurosurgery, University of São Paulo, São Paulo, São Paulo, Brazil
| |
Collapse
|
41
|
How Frequent is the One-Hour tPA Infusion Interrupted or Delayed? J Stroke Cerebrovasc Dis 2022; 31:106471. [DOI: 10.1016/j.jstrokecerebrovasdis.2022.106471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Accepted: 03/20/2022] [Indexed: 11/17/2022] Open
|
42
|
Effectiveness of Combined Thrombolysis and Mild Hypothermia Therapy in Acute Cerebral Infarction: A Meta-Analysis. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2022; 2022:4044826. [PMID: 35469165 PMCID: PMC9034919 DOI: 10.1155/2022/4044826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Revised: 03/05/2022] [Accepted: 03/18/2022] [Indexed: 11/18/2022]
Abstract
Objective To evaluate the effectiveness and safety of thrombolytic therapy combined with mild hypothermia in patients with acute cerebral infarction (ACI), based on a meta-analysis of randomized controlled trials (RCTs). Methods PubMed, EMBASE, Cochrane Library, and Chinese National Knowledge Infrastructure Database of Controlled Trials were systematically screened for randomized controlled trials (RCTs) of thrombolytic therapy combined with mild hypothermia in treating ACI from inception to January 2021. Participation and outcomes among intervention enrollees are as follows: P, participants (patients in ACI); I, interventions (thrombolysis in combination with mild hypothermia therapy); C, controls (thrombolysis merely); O, outcomes (main outcomes are the change of NIHSS, glutathione peroxidase, superoxide dismutase, malondialdehyde, inflammatory factor interleukin-1β, tumor necrosis factor-α, and adverse reaction). Following data extraction and quality assessment, a meta-analysis was performed using RevMan 5.3 software. Results A total of 26 RCTs involving 2071 patients were included. Compared to thrombolysis alone, thrombolytic therapy combined with mild hypothermia leads to better therapeutic efficacy [RR = 1.23, 95% CI (1.16, 1.31)], NIHSS [MD = -2.02, 95% CI (-2.55, -1.49)], glutathione peroxidase [MD = 8.71, 95% CI (5.55, 11.87)], superoxide dismutase [MD = 16.52, 95% CI (12.31, 19.74)], malondialdehyde [MD = -1.86, 95% CI (-1.98, -1.75)], interleukin-1β [MD = -3.48, 95% CI (-4.88, -2.08)], tumor necrosis factor-α [MD = -0.46, 95% CI (-3.39, 2.48)], and adverse reaction [RR = 0.87, 95% CI (0.63, 1.20)]. Conclusions Thrombolytic therapy combined with mild hypothermia demonstrates a beneficial role in reducing brain nerve function impairment and inflammatory reactions in ACI subjects analysed in this meta-analysis.
Collapse
|
43
|
de Souza AC, Sebastian IA, Wan Asyraf WZ, Nasreldein A, Bazadona D, Amaya P, Elkady A, Gebrewold MA, Vorasayan P, Yeghiazaryan N, Michel P, Khatri P, Pandian JD, Martins SCO, Hacke W, Lioutas VA. Regional and national differences in stroke thrombolysis use and disparities in pricing, treatment availability and coverage. Int J Stroke 2022; 17:990-996. [PMID: 35137645 DOI: 10.1177/17474930221082446] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Major disparities have been reported in recombinant tissue Plasminogen Activator (rtPA) availability among countries of different socioeconomic status. AIMS To characterize variability of rtPA price, its availability, and its association with and impact on each country's health expenditure (HE) resources. METHODS We conducted a global survey to obtain information on rtPA price (50mg vial, 2020 US Dollars) and availability. Country-specific data, including Low, Lower Middle (LMIC), Upper Middle (UMIC) and High-Income Country (HIC) classifications, and Gross Domestic Product (GDP) and HE, both nominally and adjusted for purchasing power parity (PPP), were obtained from World Bank Open Data. To assess the impact of rtPA cost, we computed the rtPA price as percentage of per capita GDP and HE and examined its association with the country income classification. RESULTS rtPA is approved and available in 109 countries. We received surveys from 59 countries: 27 (46%) HIC, 20 (34%) UMIC and 12 (20%) LMIC. Although HIC have significantly higher per capita GDP and HE compared to UMIC and LMIC (p<0.0001), the median price of rtPA is non-significantly higher in LMICs [USD 755, IQR (575-1300)] compared to UMICs [USD 544, IQR (400-815)] and HIC [USD 600, IQR (526-1000)]. In LMIC, rtPA cost accounts for 217.4% (IQR (27.1-340.6%) of PPP-adjusted per capita HE, compared to 17.6% (IQR [11.2-28.7%], p<0.0001) for HICs. CONCLUSIONS We documented significant rtPA availability and variability in its price among countries. Relative costs are higher in lower income countries, exceeding the available HE. Concerted efforts to improve rtPA affordability in low-income settings are necessary.
Collapse
Affiliation(s)
| | | | - Wan Zaidi Wan Asyraf
- Medical Department, Universiti Kebangsaan Malaysia Medical Center, Kuala Lumpur, Malaysia 60607
| | - Ahmed Nasreldein
- Department of Neurology and Psychiatry, Assuit University, Assuit, Egypt 68797
| | - Danira Bazadona
- Department of Neurology, University Hospital Centre Zagreb, Croatia 567843
| | - Pablo Amaya
- Department of Neurology, Stroke Program, Fundación Valle del Lili, Cali, Colombia 67597
| | - Ahmed Elkady
- Department of Neurology, Saudi German Hospital, Jeddah, Saudi Arabia 48051
| | | | - Pongpat Vorasayan
- Department of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand 26683
| | - Nune Yeghiazaryan
- Department of Neurology, Stroke Unit, Erebouni Medical Center, Yerevan, Armenia 366969
| | - Patrik Michel
- Stroke Center, Neurology Service, Department of Clinical Neurosciences, Neurology Service, Lausanne University Hospital, Lausanne, Switzerland
| | - Pooja Khatri
- Department of Neurology, Vascular Neurology Division, University of Cincinnati 2514
| | | | | | - Werner Hacke
- Senior professor, University of Heidelberg, Heidelberg, Germany
| | | |
Collapse
|
44
|
Podlasek A, Dhillon PS, Butt W, Grunwald IQ, England TJ. To bridge or not to bridge: summary of the new evidence in endovascular stroke treatment. Stroke Vasc Neurol 2022; 7:179-181. [PMID: 35105731 PMCID: PMC9240584 DOI: 10.1136/svn-2021-001465] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Accepted: 01/20/2022] [Indexed: 11/04/2022] Open
Affiliation(s)
- Anna Podlasek
- Tayside Innovation MedTech Ecosystem (TIME), University of Dundee, Dundee, UK .,NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, UK
| | - Permesh Singh Dhillon
- NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, UK.,Interventional Neuroradiology, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Waleed Butt
- Interventional Neuroradiology, Nottingham University Hospitals NHS Trust, Nottingham, UK.,Interventional Neuroradiology, University Hospitals Birmingham NHS Trust, Birmingham, UK
| | - Iris Q Grunwald
- Tayside Innovation MedTech Ecosystem (TIME), University of Dundee, Dundee, UK
| | - Timothy J England
- Stroke, Division of Mental Health and Clinical Neurosciences, School of Medicine, University of Nottingham, Nottingham, UK.,Stroke, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK
| |
Collapse
|
45
|
Noh L, Pham F, Haddad L, Burkhard T, Paletz L, Pech M, Lewis M, Manoukian V, Schlick KH, Song S. A practice game changer: Impact of tenecteplase for acute ischemic stroke in a multicenter quality improvement project. Am J Health Syst Pharm 2022; 79:e149-e153. [PMID: 35037028 DOI: 10.1093/ajhp/zxab482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
PURPOSE Tenecteplase is a thrombolytic that is more fibrin specific, has a longer half-life, and is easier to administer than alteplase for acute ischemic stroke (AIS). This article outlines the pharmacy experience and perspective on implementation of tenecteplase as the treatment of choice for AIS. SUMMARY Tenecteplase has been of increasing interest for AIS and is currently being studied in several clinical trials. Although it is not indicated by the Food and Drug Administration for AIS, several published studies and an update to stroke guidelines from the American Heart Association and American Stroke Association support its use in this setting. In January 2021, Cedars-Sinai Health System made the decision to add tenecteplase to the formulary for AIS in addition to keeping alteplase for patients who met the criterion of being outside the 4.5-hour window following stroke onset. Along with the added benefits of having tenecteplase on formulary come challenges of managing multiple thrombolytics for the same indication. Identifying key stakeholders and creating an interdisciplinary team are critical to ensure safe transitions. CONCLUSION Institutions can safely transition from alteplase to tenecteplase as a thrombolytic of choice for AIS.
Collapse
Affiliation(s)
- Lydia Noh
- Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Felix Pham
- Torrance Memorial Medical Center, Torrance, CA, USA
| | - Lara Haddad
- Cedars-Sinai Marina Del Rey Hospital, Marina Del Rey, CA, USA
| | | | | | - Marco Pech
- Torrance Memorial Medical Center, Torrance, CA, USA
| | - Maya Lewis
- Cedars-Sinai Marina Del Rey Hospital, Marina Del Rey, CA, USA
| | | | | | - Shlee Song
- Cedars-Sinai Medical Center, Los Angeles, CA, USA
| |
Collapse
|
46
|
Hailu K, Cannon C, Hayes S. Tenecteplase use in the management of acute ischemic stroke: Literature review and clinical considerations. Am J Health Syst Pharm 2022; 79:944-949. [PMID: 35020806 DOI: 10.1093/ajhp/zxac010] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
DISCLAIMER In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. PURPOSE Several research articles have been published within the last decade comparing the use of tenecteplase to alteplase in ischemic stroke management. Prior reporting on the comparative therapeutic efficacy and safety profiles of tenecteplase and alteplase is reviewed. SUMMARY Tenecteplase is a variant of native tissue-type plasminogen activator, which rapidly promotes thrombolysis by catalyzing formation of the serine protease plasmin. Tenecteplase has theoretical advantages over alteplase as it has greater fibrin specificity and has a longer half-life than alteplase. This allows the administration of a single bolus over 5 to 10 seconds, as opposed to a bolus followed by a 1-hour infusion with alteplase. While currently approved by the Food and Drug Administration for the treatment of ST-segment elevation myocardial infarction, tenecteplase has also been studied in the treatment of acute ischemic stroke and has extensive data for this off-label indication. The most comprehensive trials to date evaluating the use of tenecteplase in acute ischemic stroke include the TNK-S2B, Australian TNK, ATTEST, Nor-Test, and EXTEND-IA TNK trials. Findings from these randomized controlled studies suggest that tenecteplase is at least as efficacious as alteplase in terms of neurological outcomes. The majority of these studies also reported a trend toward improved safety profiles with the use of tenecteplase. CONCLUSION Current clinical evidence shows that tenecteplase is not inferior to alteplase for the treatment of ischemic stroke and suggests that tenecteplase may have a superior safety profile. Furthermore, tenecteplase also has practical advantages in terms of its administration. This can potentially lead to a decrease in medication errors and improvement in door to thrombolytic time.
Collapse
Affiliation(s)
- Kirubel Hailu
- Department of Pharmacy, Ascension St. Vincent's Riverside, Jacksonville, FL, USA
| | - Chad Cannon
- Department of Pharmacy, Ascension St. Vincent's Riverside, Jacksonville, FL, USA
| | - Sarah Hayes
- Department of Pharmacy, Ascension St. Vincent's Riverside, Jacksonville, FL, USA
| |
Collapse
|
47
|
Li G, Wang C, Wang S, Xiong Y, Zhao X. Tenecteplase in Ischemic Stroke: Challenge and Opportunity. Neuropsychiatr Dis Treat 2022; 18:1013-1026. [PMID: 35586365 PMCID: PMC9109727 DOI: 10.2147/ndt.s360967] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Accepted: 04/15/2022] [Indexed: 11/30/2022] Open
Abstract
PURPOSE OF REVIEW Intravenous thrombolysis is the first-line therapy for ischemic stroke, and alteplase has been used as an intravenous thrombolysis drug for over 20 years. However, considering its low rate of recanalization and risk of intracerebral hemorrhage, alteplase may not be the optimal thrombolytic drug of choice for ischemic stroke. Tenecteplase (TNK) is a genetically engineered, mutant, tissue plasminogen activator that is a potential substitute to alteplase in ischemic stroke. The pharmacokinetic advantages of TNK include greater fibrin selectivity than alteplase and prolonged half-life time. In this review, we have summarized the clinical trials of TNK in ischemic stroke. RECENT FINDINGS Clinical trials showed a higher recanalization rate of TNK over alteplase without increasing the rate of intracerebral hemorrhage. However, not all clinical trials showed superiority of TNK over alteplase in functional outcomes and early neurological improvement. TNK was superior to alteplase in terms of recanalization in patients who fulfilled the imaging mismatch criteria and in those planning to undergo mechanical thrombectomy. SUMMARY TNK has the potential to substitute alteplase for ischemic stroke therapy. Future TNK clinical trials that target functional outcomes are warranted.
Collapse
Affiliation(s)
- Guangshuo Li
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Chuanying Wang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China
| | - Shang Wang
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.,China National Clinical Research Center for Neurological Diseases, Beijing, People's Republic of China
| | - Yunyun Xiong
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.,China National Clinical Research Center for Neurological Diseases, Beijing, People's Republic of China.,Chinese Institute of Brain Research, Beijing, People's Republic of China
| | - Xingquan Zhao
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.,China National Clinical Research Center for Neurological Diseases, Beijing, People's Republic of China
| |
Collapse
|
48
|
Nepal G. Low-cost alternatives for the management of acute ischemic stroke in low and middle-income countries. Ann Med Surg (Lond) 2021; 72:102969. [PMID: 34992776 PMCID: PMC8712992 DOI: 10.1016/j.amsu.2021.102969] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2021] [Revised: 10/16/2021] [Accepted: 10/16/2021] [Indexed: 11/20/2022] Open
Abstract
Acute ischemic stroke (AIS) patients arriving within a suitable time frame are treated with recanalization therapy i.e. intravenous thrombolysis (IVT) with alteplase and/or mechanical thrombectomy (MT). IVT with alteplase is indicated in AIS patients presenting within 4.5 hours of onset regardless of vascular territory involved. MT is indicated in AIS patients presenting within 24 hours of onset with large vessel occlusion in the anterior circulation. However, MT is ludicrously expensive and requires exorbitant setup, devices, and expertise which is not currently feasible in LMICs. Therefore, in LMICs the only feasible recanalization option left for AIS patients is IVT. The cost of IVT varies across the LMICs, however, most of them cost around 2000-5000 USD. Apart from IVT, patients with AIS often have other significant medical costs including those for neuroimaging, intensive care, and prolonged rehabilitative treatment. In LMICs, these costs can only be afforded by a handful of patients. The majority of the LMICs have health insurance in their infancy and family members of AIS patients opt-out IVT due to the economic burden. In general, the current treatment guidelines for AIS are not very useful in LMICs because of cost-related issues among several other factors. In this editorial, we discuss evidence for alternative treatment strategies that can help tackle the rising epidemic of AIS in poor countries by improvising on existing clinical guidelines and seeking alternative treatment regimens.
Collapse
Affiliation(s)
- Gaurav Nepal
- Department of Internal Medicine, Maharajgunj Medical Campus, Tribhuvan University Institute of Medicine, Kathmandu, 44600, Nepal
| |
Collapse
|
49
|
Gerschenfeld G, Smadja D, Turc G, Olindo S, Laborne FX, Yger M, Caroff J, Gonçalves B, Seners P, Cantier M, l'Hermitte Y, Aghasaryan M, Alecu C, Marnat G, Ben Hassen W, Kalsoum E, Clarençon F, Piotin M, Spelle L, Denier C, Sibon I, Alamowitch S, Chausson N. Functional Outcome, Recanalization, and Hemorrhage Rates After Large Vessel Occlusion Stroke Treated With Tenecteplase Before Thrombectomy. Neurology 2021; 97:e2173-e2184. [PMID: 34635558 DOI: 10.1212/wnl.0000000000012915] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Accepted: 09/21/2021] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND AND OBJECTIVES To investigate in routine care the efficacy and safety of IV thrombolysis (IVT) with tenecteplase prior to mechanical thrombectomy (MT) in patients with large vessel occlusion acute ischemic strokes (LVO-AIS), either secondarily transferred after IVT or directly admitted to a comprehensive stroke center (CSC). METHODS We retrospectively analyzed clinical and procedural data of patients treated with 0.25 mg/kg tenecteplase within 270 minutes of LVO-AIS who underwent brain angiography. The main outcome was 3-month functional independence (modified Rankin Scale score ≤2). Recanalization (revised Treatment in Cerebral Ischemia score 2b-3) was evaluated before (pre-MT) and after MT (final). RESULTS We included 588 patients (median age 75 years [interquartile range (IQR) 61-84]; 315 women [54%]; median NIH Stroke Scale score 16 [IQR 10-20]), of whom 520 (88%) were secondarily transferred after IVT. Functional independence occurred in 47% (n = 269/570; 95% confidence interval [CI] 43.0-51.4) of patients. Pre-MT recanalization occurred in 120 patients (20.4%; 95% CI 17.2-23.9), at a similar rate across treatment paradigms (direct admission, n = 14/68 [20.6%]; secondary transfer, n = 106/520 [20.4%]; p > 0.99) despite a shorter median IVT to puncture time in directly admitted patients (38 [IQR 23-55] vs 86 [IQR 70-110] minutes; p < 0.001). Final recanalization was achieved in 492 patients (83.7%; 95%CI 80.4-86.6). Symptomatic intracerebral hemorrhage occurred in 2.5% of patients (n = 14/567; 95% CI 1.4-4.1). DISCUSSIONS Tenecteplase before MT is safe, effective, and achieves a fast recanalization in everyday practice in patients secondarily transferred or directly admitted to a CSC, in line with published results. These findings should encourage its wider use in bridging therapy. CLASSIFICATION OF EVIDENCE This study provides Class IV evidence that tenecteplase within 270 minutes of LVO-AIS increases the probability of functional independence.
Collapse
Affiliation(s)
- Gaspard Gerschenfeld
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Didier Smadja
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Guillaume Turc
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Stephane Olindo
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - François-Xavier Laborne
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Marion Yger
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Jildaz Caroff
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Bruno Gonçalves
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Pierre Seners
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Marie Cantier
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Yann l'Hermitte
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Manvel Aghasaryan
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Cosmin Alecu
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Gaultier Marnat
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Wagih Ben Hassen
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Erwah Kalsoum
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Frédéric Clarençon
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Michel Piotin
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Laurent Spelle
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Christian Denier
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Igor Sibon
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Sonia Alamowitch
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France
| | - Nicolas Chausson
- From the Service des Urgences cérébro-vasculaires (G.G., M.Y., M.C., S.A.), Hôpital Pitié-Salpêtrière, Hôpital Saint-Antoine, APHP; Faculté de Médecine (G.G.), Sorbonne Université, Paris; Service de Neurologie, Unité Neuro-vasculaire (D.S., Y.H., M.A., C.A., N.C.), and Unité de Recherche Clinique (F.-X.L.), Hôpital Sud Francilien, Corbeil-Essonnes; Services de Neurologie (G.T., B.G., P.S.) and Neuroradiologie (W.B.H.), GHU Paris Psychiatrie et Neurosciences, Université de Paris, INSERM U1266, FHU Neurovasc; Service de Neurologie, Unité Neuro-vasculaire (S.O., I.S.), and Service de Neuroradiologie Diagnostique et Interventionnelle (G.M.), CHU de Bordeaux; Service de Neuroradiologie Interventionnelle (NEURI) (J.C., L.S.) and Service de Neurologie (C.D.), Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre; Service de Neuroradiologie (E.K.), Hôpital Henri-Mondor, AP-HP, Créteil; Service de Neuroradiologie (F.C.), Hôpital Pitié-Salpêtrière, AP-HP; Service de Neuroradiologie Interventionnelle (M.P.), Hôpital Fondation Rothschild, Paris; and CRSA (S.A.), Sorbonne Université, INSERM, UMRS 938, Hôpital Saint-Antoine, Paris, France.
| | | |
Collapse
|
50
|
Dong Y, Sui Y, Cheng X, Wang DZ. Is tenecteplase ready to replace alteplase to treat acute ischaemic stroke? The knowns and unknowns. Stroke Vasc Neurol 2021; 7:1-5. [PMID: 34667106 PMCID: PMC8899685 DOI: 10.1136/svn-2021-001321] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2021] [Accepted: 09/13/2021] [Indexed: 11/04/2022] Open
Affiliation(s)
- Yi Dong
- Department of Neurology, Huashan Hospital Fudan University, Shanghai, China
| | - Yi Sui
- Department of Neurology, Shenyang Brain Hospital, Shenyang Medical College, Shenyang, China.,Department of Neurology, The First People's Hospital of Shenyang, Shenyang, China
| | - Xin Cheng
- Department of Neurology, Huashan Hospital Fudan University, Shanghai, China
| | - David Z Wang
- Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, USA
| |
Collapse
|